<SEC-DOCUMENT>0001213900-21-061610.txt : 20211123
<SEC-HEADER>0001213900-21-061610.hdr.sgml : 20211123
<ACCEPTANCE-DATETIME>20211123163037
ACCESSION NUMBER:		0001213900-21-061610
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20211117
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20211123
DATE AS OF CHANGE:		20211123

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CHINA PHARMA HOLDINGS, INC.
		CENTRAL INDEX KEY:			0001106644
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				731564807
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34471
		FILM NUMBER:		211438914

	BUSINESS ADDRESS:	
		STREET 1:		2ND FLOOR, NO. 17, JINPAN ROAD
		STREET 2:		HAIKOU
		CITY:			HAINAN PROVINCE
		STATE:			F4
		ZIP:			570216
		BUSINESS PHONE:		8689866811730

	MAIL ADDRESS:	
		STREET 1:		2ND FLOOR, NO. 17, JINPAN ROAD
		STREET 2:		HAIKOU
		CITY:			HAINAN PROVINCE
		STATE:			F4
		ZIP:			570216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TS ELECTRONICS INC
		DATE OF NAME CHANGE:	20030818

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SOFTSTONE INC
		DATE OF NAME CHANGE:	20030128

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SOFTSTONE INC /DE/
		DATE OF NAME CHANGE:	20010808
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea151262-8k_chinapharma.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:CPHI="http://chinapharmaholdings.com/20211117">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_030_CPHI_chinapharmaholdings.com_20211117 -->
<!-- Field: Set; Name: xdx; ID: xdx_040_20211117_20211117 -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DEntityCentralIndexKey_0001106644 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-11-17to2021-11-17" name="dei:EntityCentralIndexKey">0001106644</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-11-17to2021-11-17" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-11-17to2021-11-17" id="xdx2ixbrl0018" name="dei:EntityAddressCountry">CN</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="cphi-20211117.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-11-17to2021-11-17">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001106644</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-11-17</xbrli:startDate>
        <xbrli:endDate>2021-11-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90A_edei--DocumentType_c20211117__20211117_zHtJ6d6jrcH5"><ix:nonNumeric contextRef="From2021-11-17to2021-11-17" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<span id="xdx_903_edei--DocumentPeriodEndDate_c20211117__20211117_zGXqYUZOXt3d"><ix:nonNumeric contextRef="From2021-11-17to2021-11-17" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">November 17, 2021</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_909_edei--EntityRegistrantName_c20211117__20211117_z2g51xfQOXLk"><ix:nonNumeric contextRef="From2021-11-17to2021-11-17" name="dei:EntityRegistrantName">CHINA PHARMA HOLDINGS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of Registrant as specified in charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: white">
    <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><span id="xdx_909_edei--EntityIncorporationStateCountryCode_c20211117__20211117_zZgbolQ84X2h"><ix:nonNumeric contextRef="From2021-11-17to2021-11-17" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><span id="xdx_908_edei--EntityFileNumber_c20211117__20211117_zOx3eYPULZ23"><ix:nonNumeric contextRef="From2021-11-17to2021-11-17" name="dei:EntityFileNumber">001-34471</ix:nonNumeric></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><span id="xdx_904_edei--EntityTaxIdentificationNumber_c20211117__20211117_zNPT1E5iHTu5"><ix:nonNumeric contextRef="From2021-11-17to2021-11-17" name="dei:EntityTaxIdentificationNumber">73-1564807</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: center">(State or other jurisdiction</td>
    <td>&#160;</td>
    <td style="text-align: center">(Commission File No.)</td>
    <td>&#160;</td>
    <td style="text-align: center">(IRS Employer</td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td style="text-align: center">of Incorporation)</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: center">Identification No.)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-decoration: underline"><span id="xdx_907_edei--EntityAddressAddressLine1_c20211117__20211117_zvRw6lSOeLT1"><ix:nonNumeric contextRef="From2021-11-17to2021-11-17" name="dei:EntityAddressAddressLine1">Second Floor, No. 17</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressAddressLine2_c20211117__20211117_zFXyemaXgx44"><ix:nonNumeric contextRef="From2021-11-17to2021-11-17" name="dei:EntityAddressAddressLine2">Jinpan Road</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-decoration: underline">Haikou, <span id="xdx_902_edei--EntityAddressCityOrTown_c20211117__20211117_zykE4MzVC5Fb"><ix:nonNumeric contextRef="From2021-11-17to2021-11-17" name="dei:EntityAddressCityOrTown">Hainan Province</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressCountry_dxL_c20211117__20211117_znZmrjMZ1Zwi" title="::XDX::CN"><span style="-sec-ix-hidden: xdx2ixbrl0018">China</span></span> <span id="xdx_901_edei--EntityAddressPostalZipCode_c20211117__20211117_zLPHrcYNAVrc"><ix:nonNumeric contextRef="From2021-11-17to2021-11-17" name="dei:EntityAddressPostalZipCode">570216</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices) (Zip Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including area code:
<span style="text-decoration: underline">+<span id="xdx_90E_edei--CityAreaCode_c20211117__20211117_zmiv6KcaAh3f"><ix:nonNumeric contextRef="From2021-11-17to2021-11-17" name="dei:CityAreaCode">86</ix:nonNumeric></span> <span id="xdx_900_edei--LocalPhoneNumber_c20211117__20211117_zg37S2MNCkDk"><ix:nonNumeric contextRef="From2021-11-17to2021-11-17" name="dei:LocalPhoneNumber">898-6681-1730</ix:nonNumeric></span> (China)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_edei--WrittenCommunications_c20211117__20211117_zPUY77FVNGP2"><ix:nonNumeric contextRef="From2021-11-17to2021-11-17" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify">Written communications pursuant to Rule 425 under the Securities
Act (17CFR230.425)</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90C_edei--SolicitingMaterial_c20211117__20211117_zd8eA5jYUd0b"><ix:nonNumeric contextRef="From2021-11-17to2021-11-17" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify">Soliciting material pursuant to Rule14a-12 under the Exchange
Act (17CFR240.14a-12)</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_edei--PreCommencementTenderOffer_c20211117__20211117_z8wOt0JDtlo6"><ix:nonNumeric contextRef="From2021-11-17to2021-11-17" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17CFR240.14d-2(b))</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90A_edei--PreCommencementIssuerTenderOffer_c20211117__20211117_zurpB9g9jrk7"><ix:nonNumeric contextRef="From2021-11-17to2021-11-17" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17CFR240.13e-4(c))</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 34%; text-align: center"><b>Title of each class</b></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 31%; text-align: center; text-indent: 4.15pt"><b>Trading Symbol(s)</b></td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 33%; text-align: center"><b>Name of each exchange on which registered</b></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span id="xdx_905_edei--Security12bTitle_c20211117__20211117_zyG6hUo9gxR8"><ix:nonNumeric contextRef="From2021-11-17to2021-11-17" name="dei:Security12bTitle">Common Stock</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_902_edei--TradingSymbol_c20211117__20211117_zHnPipQwmY64"><ix:nonNumeric contextRef="From2021-11-17to2021-11-17" name="dei:TradingSymbol">CPHI</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_907_edei--SecurityExchangeName_c20211117__20211117_zdkcubGqDGz2"><ix:nonNumeric contextRef="From2021-11-17to2021-11-17" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NYSE American</ix:nonNumeric></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20211117__20211117_zT8gCMw6ps35"><ix:nonNumeric contextRef="From2021-11-17to2021-11-17" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Item 1.01.</b> <b>Entry into a Material Definitive Agreement.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On November 17, 2021,
China Pharma Holdings, Inc. (the &#8220;Company&#8221;) entered into a Securities Purchase Agreement (the &#8220;Agreement&#8221;) pursuant
to which the Company issued an unsecured convertible promissory note (the &#8220;Note&#8221;) to an institutional accredited investor
Streeterville Capital, LLC (&#8220;Investor&#8221;). The Note shall mature fifteen (15) months after the purchase price of the Note is
delivered from the Investor to the Company (the &#8220;Purchase Price Date&#8221;). The Note has the original principal amount of $5,250,000
and Investor gave consideration of $5,000,000, reflecting original issue discount of $250,000. The transaction contemplated under the
Agreement was closed on November 19, 2021 and the Company anticipates using the proceeds for general working capital purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Interest accrues on the
outstanding balance of the Note at 5% per annum. Upon the occurrence of an Event of Default as defined in the Note, interest accrues at
the lesser of 22% per annum or the maximum rate permitted by applicable law. In addition, upon any Event of Default, the Investor may
accelerate the outstanding balance payable under the Note, which will increase automatically upon such acceleration by 15% or 5%, depending
on the nature of the Event of Default.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Pursuant to the terms
of the Agreement and the Note, the Company must obtain Investor&#8217;s consent for certain fundamental transactions such as consolidation,
merger with or into another entity (excerpt for a reincorporation merger), disposition of substantial assets, change of control, reorganization
or recapitalization. Any occurrence of a fundamental transaction without Investor&#8217;s prior written consent will be deemed an Event
of Default.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Investor may redeem all
or any part the outstanding balance of the Note, subject to $500,000 per calendar month, at any time after one hundred twenty-one (121)
days from the Purchase Price Date upon three trading days&#8217; notice, in cash or converting into shares of the Company&#8217;s common
stock, par value $0.001 (&#8220;Common Stock&#8221;) at a price equal to 85% multiplied by the lowest daily VWAP during the ten (10) trading
days immediately preceding the applicable redemption conversion, subject to certain adjustments and ownership limitations specified in
the Note. The Note provides for liquidated damages upon failure to comply with any of the terms or provisions of the Note. The Company
may prepay the outstanding balance of the Note with the Investor&#8217;s consent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Pursuant to the terms
of the Agreement, the Company will reserve 30,000,000 shares of Common Stock from its authorized and unissued Common Stock to provide
for all issuances of Common Stock under the Note (the &#8220;Share Reserve&#8221;). The Company further agrees to add additional shares
of Common Stock to the Share Reserve in increments of 1,000,000 shares under certain circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company relied on
the exemption from registration afforded by Section 4(a)(2) of the Securities Act of 1933 and <span style="background-color: white">Regulation
D promulgated thereunder</span> in connection with the issuance and sale of the Note and underlying shares of Common Stock. The underlying
shares of Common Stock in connection with the issuance and sale of the Note may be issued pursuant to the Company&#8217;s effective shelf
registration statement. The Company agreed, within thirty (30) days of the issuance and sale of the Note, to file with the Securities
and Exchange Commission a prospectus supplement pursuant to Rule 424(b) of the Securities Act registering $5,000,000 in Common Stock for
the benefit of Investor.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The foregoing description
is qualified in its entirety by reference to the full text of the Note and the Agreement, a copy of each of which is filed as Exhibit
4.1 and Exhibit 10.1 hereto, and each of which is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Item 2.03.</b> <b>Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The information in Item
1.01 is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><b>Item 9.01</b> <b>Financial Statements and Exhibits.</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"> (d) Exhibits.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is filed as an exhibit to this report:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; padding: 0.25pt 0.25pt 0.75pt; width: 9%"><b>Exhibit Number</b></td>
    <td style="padding: 0.25pt; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; padding: 0.25pt 0.25pt 0.75pt; width: 90%"><b>Exhibit</b></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0.25pt">4.1</td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt"><a href="ea151262ex4-1_chinapharma.htm">Convertible Promissory Note dated November 17, 2021</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding: 0.25pt">10.1</td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt; text-align: justify"><a href="ea151262ex10-1_chinapharma.htm">Securities Purchase Agreement between China Pharma Holdings, Inc. and Streeterville Capital, LLC dated November 17, 2021</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0.25pt">104</td>
    <td style="padding: 0.25pt">&#160;</td>
    <td style="padding: 0.25pt; text-align: justify">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
  </table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: November 23, 2021</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: #FEFEFE">
    <td>&#160;</td>
    <td colspan="2"><b>CHINA PHARMA HOLDINGS, INC.</b></td></tr>
  <tr style="background-color: #FEFEFE">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="background-color: #FEFEFE">
    <td style="padding-bottom: 1.5pt; width: 60%">&#160;</td>
    <td style="padding-bottom: 1.5pt; width: 5%">By:</td>
    <td style="border-bottom: Black 1.5pt solid; width: 35%">/s/ Zhilin Li</td></tr>
  <tr style="background-color: #FEFEFE">
    <td>&#160;</td>
    <td>Name:</td>
    <td> Zhilin Li</td></tr>
  <tr style="background-color: #FEFEFE">
    <td>&#160;</td>
    <td>Title:</td>
    <td>President and Chief Executive Officer</td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">2</p>

<!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5Fk1aROijRUWsIkXE12i3EmyzZZP6cyRvaWwRl4VlmflmhBiJFS1NjQyneZHDAZu21h6hwAoZ7QWDI1tvUgi3wKtxnrX1/fsDMwoMBmY6VvIchN56Nw7LFJSaxMkkViCTVM5gvxXRV8/IVqZE642uQdsS9kwtG/SaX0PCQT/JUvPqq47IzpANcWM5yG+IpYphR3f9IL45yPNMRKN+IrFi6tpvTec8NbCosQldbkD/G30AE11JQg== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ea151262ex4-1_chinapharma.htm
<DESCRIPTION>CONVERTIBLE PROMISSORY NOTE DATED NOVEMBER 17, 2021
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>CONVERTIBLE PROMISSORY NOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 51%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">November 17, 2021</FONT></TD>
    <TD STYLE="text-align: right; width: 49%; padding-left: 147pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. $5,250,000.00</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">FOR VALUE RECEIVED,
CHINA PHARMA HOLDINGS, INC., a Nevada corporation (&ldquo;<B>Borrower</B>&rdquo;), promises to pay to STREETERVILLE CAPITAL, LLC, a Utah
limited liability company, or its successors or assigns (&ldquo;<B>Lender</B>&rdquo;), $5,250,000.00 and any interest, fees, charges,
and late fees accrued hereunder on the date that is fifteen (15) months after the Purchase Price Date (the &ldquo;<B>Maturity Date</B>&rdquo;)
in accordance with the terms set forth herein and to pay interest on the Outstanding Balance at the rate of five percent (5%) per annum
from the Purchase Price Date until the same is paid in full. All interest calculations hereunder shall be computed on the basis of a 360-day
year comprised of twelve (12) thirty (30) day months, shall compound daily and shall be payable in accordance with the terms of this Note.
This Convertible Promissory Note (this &ldquo;<B>Note</B>&rdquo;) is issued and made effective as of November 17, 2021 (the &ldquo;<B>Effective
Date</B>&rdquo;). This Note is issued pursuant to that certain Securities Purchase Agreement dated November 17, 2021, as the same may
be amended from time to time, by and between Borrower and Lender (the &ldquo;<B>Purchase Agreement</B>&rdquo;). Certain capitalized terms
used herein are defined in <U>Attachment 1</U> attached hereto and incorporated herein by this reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">This Note carries
an OID of $250,000.00, which amount is fully earned and included in the initial principal balance of this Note. In addition, Borrower
agrees to pay $15,000.00 to Lender to cover Lender&rsquo;s legal fees, accounting costs, due diligence, monitoring and other transaction
costs incurred in connection with the purchase and sale of this Note (the &ldquo;<B>Transaction Expense Amount</B>&rdquo;). The purchase
price for this Note shall be $5,000,000.00 (the &ldquo;<B>Purchase Price</B>&rdquo;), computed as follows: $5,250,000.00 original principal
balance, less the OID. The Purchase Price shall be payable by Lender by wire transfer of immediately available funds. The Transaction
Expense Amount will be deducted from the amount funded hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> 1. <U>Payment; Prepayment; Use of Proceeds</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">1.1. <U>Payment</U>.
All payments owing hereunder shall be in lawful money of the United States of America or Conversion Shares (as defined below), as provided
for herein, and delivered to Lender at the address or bank account furnished to Borrower for that purpose. All payments shall be applied
first to (a) costs of collection, if any, then to (b) fees and charges, if any, then to (c) accrued and unpaid interest, and thereafter,
to (d) principal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">1.2. <U>Prepayment</U>.
Notwithstanding the foregoing, Borrower may, with Lender&rsquo;s consent, prepay all or any portion of the Outstanding Balance (less such
portion of the Outstanding Balance for which Borrower has received a Lender Conversion Notice (as defined below) or a Redemption Notice
(as defined below) from Lender where the applicable Conversion Shares have not yet been delivered).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> 2. <U>Security</U>. This Note is unsecured.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">3.  <U>Lender
Optional Conversion</U>. Lender has the right at any time after the Purchase Price Date until the Outstanding Balance has been paid
in full, at its election, to convert (&ldquo;<B>Lender Conversion</B>&rdquo;) all or any portion of the Outstanding Balance into
shares (each instance of conversion is referred to herein as a &ldquo;<B>Lender Conversion Shares</B>&rdquo;) of fully paid and
non-assessable shares of common stock, $0.001 par value per share (the &ldquo;<B>Common Stock</B>&rdquo;), of Borrower as per the
following conversion formula: the number of Lender Conversion Shares equals the amount being converted (the &ldquo;<B>Conversion
Amount</B>&rdquo;) divided by the Lender Conversion Price. Conversion notices in the form attached hereto as <U>Exhibit A</U> (each,
a &ldquo;<B>Lender Conversion Notice</B>&rdquo;) may be effectively delivered to Borrower by any method set forth in the
&ldquo;Notices&rdquo; Section of the Purchase Agreement, and all Lender Conversions shall be cashless and not require further
payment from Lender. Borrower shall deliver the Lender Conversion Shares from any Lender Conversion to Lender in accordance with
Section 9 below. Any amount of Lender Conversion Shares shall be subject to NYSE American 19.99% Cap, as defined under Section 11
herein, until the necessary stockholders&rsquo; approval is obtained, if the amount exceeds such limit. Any Lender Conversion Shares
issued prior to the date that is six (6) months from the Purchase Price Date must be issued pursuant to Borrower&rsquo;s Form S-3
registration statement (SEC File No. 333-251973) (the &ldquo;<B>Registration Statement</B>&rdquo;), provided the SEC or any other
regulatory body does not impose any stop order or any other restrictions on the effectiveness of the Registration Statement for
causes and/or factors out of the Company&rsquo;s control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> 4. <U>Trigger Events, Defaults and Remedies</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-size: 10pt">4.1.</FONT> <FONT STYLE="font-size: 10pt"><U>Trigger
Events</U>. The following are trigger events under this Note (each, a <B>&ldquo;Trigger Event&rdquo;)</B>: (a) Borrower fails to pay any
principal, interest, fees, charges, or any other amount when due and payable hereunder; (b) Borrower fails to deliver any Lender
Conversion Shares in accordance with the </FONT>terms hereof; (c) Borrower fails to deliver any Redemption Conversion Shares (as
defined below) in accordance with the terms hereof; (d) a receiver, trustee or other similar official shall be appointed over
Borrower or a material part of its assets and such appointment shall remain uncontested for twenty (20) days or shall not be
dismissed or discharged within sixty (60) days; (e) Borrower becomes insolvent or generally fails to pay, or admits in writing its
inability to pay, its debts as they become due, subject to applicable grace periods, if any; (f) Borrower makes a general assignment
for the benefit of creditors; (g) Borrower files a petition for relief under any bankruptcy, insolvency or similar law (domestic or
foreign); (h)&nbsp;&nbsp; an involuntary bankruptcy proceeding is commenced or filed against Borrower; (i) Borrower or any pledgor,
trustor, or guarantor of this Note defaults or otherwise fails to observe or perform any covenant, obligation, condition or
agreement of Borrower or such pledgor, trustor, or guarantor contained herein or in any other Transaction Document (as defined in
the Purchase Agreement), other than those specifically set forth in this Section 4.1 and Section 4 of the Purchase Agreement; (j)
any representation, warranty or other statement made or furnished by or on behalf of Borrower or any pledgor, trustor, or guarantor
of this Note to Lender herein, in any Transaction Document, or otherwise in connection with the issuance of this Note is false,
incorrect, incomplete or misleading in any material respect when made or furnished; (k) the occurrence of a Fundamental Transaction
without Lender&rsquo;s prior written consent; (l) Borrower fails to maintain the Share Reserve (as defined in the Purchase
Agreement); (m) any money judgment, writ or similar process is entered or filed against Borrower or any subsidiary of Borrower or
any of its property or other assets for more than $5,000,000.00, and shall remain unvacated, unbonded or unstayed for a period of
forty (40) calendar days unless otherwise consented to by Lender; or (n) Borrower fails to observe or perform any covenant set forth
in Section 4 of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">4.2. <U>Trigger Event
Remedies</U>. At any time following the occurrence of any Trigger Event, Lender may, at its option, increase the Outstanding Balance by
applying the Trigger Effect (subject to the limitation set forth below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">4.3. <U>Defaults</U>.
At any time following the occurrence of a Trigger Event, Lender may, at its option, send written notice to Borrower demanding that Borrower
cure the Trigger Event within ten (10) Trading Days. If Borrower fails to cure the Trigger Event within the required ten (10) Trading
Day cure period, the Trigger Event will automatically become an event of default hereunder (each, an &ldquo;<B>Event of Default</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">4.4. <U>Default Remedies</U>.
At any time and from time to time following the occurrence of any Event of Default, Lender may accelerate this Note by written notice
to Borrower, with the Outstanding Balance becoming immediately due and payable in cash at the Mandatory Default Amount.). Notwithstanding
the foregoing, upon the occurrence of any Trigger Event described in clauses (d), (e), (f), (g)&nbsp; or (h) of Section 4.1, an Event
of Default will be deemed to have occurred and the Outstanding Balance as of the date of the occurrence of such Trigger Event shall become
immediately and automatically due and payable in cash at the Mandatory Default Amount, without any written notice required by Lender
for the Trigger Event to become an Event of Default. At any time following the occurrence of any Event of Default, upon written notice
given by Lender to Borrower, interest shall accrue on the Outstanding Balance beginning on the date the applicable Event of Default occurred
at an interest rate equal to the lesser of twenty-two percent (22%) per annum or the maximum rate permitted under applicable law (&ldquo;<B>Default
Interest</B>&rdquo;). In connection with acceleration described herein, Lender need not provide, and Borrower hereby waives, any presentment,
demand, protest or other notice of any kind, and Lender may immediately and without expiration of any grace period enforce any and all
of its rights and remedies hereunder and all other remedies available to it under applicable law. Such acceleration may be rescinded
and annulled by Lender at any time prior to payment hereunder and Lender shall have all rights as a holder of the Note until such time,
if any, as Lender receives full payment pursuant to this Section 4.4. No such rescission or annulment shall affect any subsequent Trigger
Event or Event of Default or impair any right consequent thereon. Nothing herein shall limit Lender&rsquo;s right to pursue any other
remedies available to it at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief
with respect to Borrower&rsquo;s failure to timely deliver Conversion Shares upon Conversion of the Note as required pursuant to the
terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">5.
<U>Unconditional Obligation; No Offset</U>. Borrower acknowledges that this Note is an unconditional, valid, binding and enforceable obligation
of Borrower not subject to offset, deduction or counterclaim of any kind. Borrower hereby waives any rights of offset it now has or may
have hereafter against Lender, its successors and assigns, and agrees to make the payments or Conversions called for herein in accordance
with the terms of this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">6.
<U>Waiver</U>. No waiver of any provision of this Note shall be effective unless it is in the form of a writing signed by the party granting
the waiver. No waiver of any provision or consent to any prohibited action shall constitute a waiver of any other provision or consent
to any other prohibited action, whether or not similar. No waiver or consent shall constitute a continuing waiver or consent or commit
a party to provide a waiver or consent in the future except to the extent specifically set forth in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> 7. <U>Rights Upon Issuance of Securities</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">7.1. <U>Subsequent
Equity Sales</U>. Other than with respect to Exempt Issuances, if Borrower or any subsidiary thereof, as applicable, at any time
this Note is outstanding, shall sell, issue or grant any Common Stock, option to purchase Common Stock, right to reprice, preferred
shares convertible into Common Stock, debt, warrants, options or other instruments or securities which are convertible into or
exercisable or exchangeable for Common Stock to Lender or any third party (collectively, the &ldquo;<B>Equity
Securities</B>&rdquo;), including without limitation any Deemed Issuance, at an effective price per share less than the then
effective Lender Conversion Price (such issuance is referred to herein as a &ldquo;<B>Dilutive Issuance</B>&rdquo;), then, the
Lender Conversion Price shall be automatically reduced and only reduced to equal such lower effective price per share. If the holder
of any Equity Securities so issued shall at any time, whether by operation of purchase price adjustments, reset provisions, floating
conversion, exercise or exchange prices or otherwise, or due to warrants, options, or rights per share which are issued in
connection with such Dilutive Issuance, be entitled to receive Common Stock at an effective price per share that is less than the
Lender Conversion Price, such issuance shall be deemed to have occurred for less than the Lender Conversion Price on the date of
such Dilutive Issuance, and the then effective Lender Conversion Price shall be reduced and only reduced to equal such lower
effective price per share. Such adjustments described above to the Lender Conversion Price shall be permanent (subject to additional
adjustments under this section), and shall be made whenever such Equity Securities are issued. Borrower shall notify Lender, in
writing, no later than the Trading Day following the issuance of any Equity Securities subject to this Section 7.1, indicating
therein the applicable issuance price, or applicable reset price, exchange price, conversion price, or other pricing terms (such
notice, the &ldquo;<B>Dilutive Issuance Notice</B>&rdquo;). For purposes of clarity, whether or not Borrower provides a Dilutive
Issuance Notice pursuant to this Section 7.1, upon the occurrence of any Dilutive Issuance, on the date of such Dilutive Issuance
the Lender Conversion Price shall be lowered to equal the applicable effective price per share regardless of whether Borrower or
Lender accurately refers to such lower effective price per share in any subsequent Installment Notice or Lender Conversion
Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">7.2. <U>Adjustment
of Lender Conversion Price upon Subdivision or Combination of Common Stock</U>. Without limiting any provision hereof, if Borrower at
any time on or after the Effective Date subdivides (by any stock split, stock dividend, recapitalization or otherwise) one or more classes
of its outstanding Common Stock into a greater number of shares, the Lender Conversion Price in effect immediately prior to such subdivision
will be proportionately reduced. Without limiting any provision hereof, if Borrower at any time on or after the Effective Date combines
(by combination, reverse stock split or otherwise) one or more classes of its outstanding Common Stock into a smaller number of shares,
the Lender Conversion Price in effect immediately prior to such combination will be proportionately increased. Any adjustment pursuant
to this Section 7.2 shall become effective immediately after the effective date of such subdivision or combination. If any event requiring
an adjustment under this Section 7.2 occurs during the period that a Redemption Conversion Price is calculated hereunder, then the calculation
of such Redemption Conversion Price shall be adjusted appropriately to reflect such event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">7.3. <U>Conversion
Cap</U>. In the event the Lender Conversion Price is reduced as a result of one or more Dilutive Issuances, the most Lender shall be able
to convert at such reduced price or prices will be $1,050,000.00 (the &ldquo;<B>Conversion Cap</B>&rdquo;). Once the Conversion Cap has
been reached, the Lender Conversion Price will revert back to the original Lender Conversion Price as set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> 8. <U>Borrower Redemptions</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">8.1. <U>Redemption Conversions</U>. Beginning on the date
that is one hundred twenty-one (121)&nbsp;&nbsp; days from the Purchase Price Date, Lender shall have the right, exercisable at any
time in its sole and absolute discretion, to redeem all or any portion of the Note (such amount, the &ldquo;<B>Redemption
Amount</B>&rdquo;), subject to the Maximum Monthly Redemption Amount, by providing Borrower with a notice substantially in the form
attached hereto as <U>Exhibit B</U> (each, a &ldquo;<B>Redemption Notice</B>&rdquo;, and each date on which Lender delivers a
Redemption Notice, a &ldquo;<B>Redemption Date</B>&rdquo;). For the avoidance of doubt, Lender may submit to Borrower one (1) or
more Redemption Notices in any given calendar month; provided that the aggregate Redemption Amounts in such calendar month do not
exceed the Maximum Monthly Redemption Amount. Payments of each Redemption Amount may be made (a) in cash, or (b) by converting such
Redemption Amount into Common Stock (&ldquo;<B>Redemption Conversion Shares</B>&rdquo;, and together with the Lender Conversion
Shares, the &ldquo;<B>Conversion Shares</B>&rdquo;) in accordance with this Section 8.1 (each, a &ldquo;<B>Redemption
Conversion</B>&rdquo;) per the following formula: the number of Redemption Conversion Shares equals the portion of the applicable
Redemption Amount being converted divided by the Redemption Conversion Price, or (c) by any combination of the foregoing, so long as
the cash is delivered to Lender on the third Trading Day immediately following the applicable Redemption Date and the Redemption
Conversion Shares are delivered to Lender on or before the applicable Delivery Date (as defined below). Notwithstanding the
foregoing, Borrower will not be entitled to elect a Redemption Conversion with respect to any portion of any applicable Redemption
Amount and shall be required to pay the Redemption Amount in cash, if on the applicable Redemption Date there is an Equity
Conditions Failure, and such failure is not waived in writing by Lender. Notwithstanding the foregoing, in the event Borrower
redeems an amount equal to half of the original principal balance of this Note in cash, then any remaining redemptions Borrower
satisfies in cash will be subject to a twenty-five percent (25%) premium. Borrower shall have the right to defer payment of two
redemptions (for the purpose of clarification, the two redemptions could be any of the two redemptions hereunder during the term of
the Note) due hereunder by providing written notice to Lender at least three (3)&nbsp; Trading Days prior to the first day of each
such calendar month for which it wishes to defer redemptions for that month. In the event Borrower elects to exercise its deferral
right, the Outstanding Balance shall automatically be increased by 0.5% for each exercise of the deferral right. Any Redemption
Conversion Shares issued prior to the date that is six (6) months from the Purchase Price Date must be issued pursuant to the
Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">8.2. <U>Allocation
of Redemption Amounts</U>. Following its receipt of a Redemption Notice, Borrower may either ratify Lender&rsquo;s proposed allocation
in the applicable Redemption Notice or elect to change the allocation by written notice to Lender by email or fax within twenty-four (24)
hours of its receipt of such Redemption Notice, so long as the sum of the cash payments and the amount of Redemption Conversions equal
the applicable Redemption Amount. If Borrower fails to notify Lender of its election to change the allocation prior to the deadline set
forth in the previous sentence, it shall be deemed to have ratified and accepted the allocation set forth in the applicable Redemption
Notice prepared by Lender. Borrower acknowledges and agrees that the amounts and calculations set forth thereon are subject to correction
or adjustment because of error, mistake, or any adjustment resulting from a Trigger Event or other adjustment permitted under the Transaction
Documents (an &ldquo;<B>Adjustment</B>&rdquo;). Furthermore, no error or mistake in the preparation of such notices, or failure to apply
any Adjustment that could have been applied prior to the preparation of a Redemption Notice may be deemed a waiver of Lender&rsquo;s right
to enforce the terms of any Note, even if such error, mistake, or failure to include an Adjustment arises from Lender&rsquo;s own calculation.
Borrower shall deliver the Redemption Conversion Shares from any Redemption Conversion to Lender in accordance with Section 9 below on
or before each applicable Delivery Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">9.
<U>Method of Conversion Share Delivery</U>. On or before the close of business on the fifth (5<SUP>th</SUP>) Trading Day following each
Redemption Date or the fifth (5<SUP>th</SUP>) Trading Day following the date of delivery of a Lender Conversion Notice, as applicable
(the &ldquo;<B>Delivery Date</B>&rdquo;), Borrower shall, provided it is DWAC Eligible at such time and such Conversion Shares are eligible
for delivery via DWAC, deliver or cause its transfer agent to deliver the applicable Conversion Shares electronically via DWAC to the
account designated by Lender in the applicable Lender Conversion Notice or Redemption Notice. If Borrower is not DWAC Eligible or such
Conversion Shares are not eligible for delivery via DWAC, it shall deliver to Lender or its broker (as designated in the Lender Conversion
Notice or Redemption Notice), via reputable overnight courier, a certificate representing the number of shares of Common Stock equal to
the number of Conversion Shares to which Lender shall be entitled, registered in the name of Lender or its designee. For the avoidance
of doubt, Borrower has not met its obligation to deliver Conversion Shares by the Delivery Date unless Lender or its broker, as applicable,
has actually received the certificate representing the applicable Conversion Shares no later than the close of business on the relevant
Delivery Date pursuant to the terms set forth above. Moreover, and notwithstanding anything to the contrary herein or in any other Transaction
Document, in the event Borrower or its transfer agent refuses to deliver any Conversion Shares without a restrictive securities legend
to Lender on grounds that such issuance is in violation of Rule 144 under the Securities Act of 1933, as amended (&ldquo;<B>Rule 144</B>&rdquo;),
Borrower shall deliver or cause its transfer agent to deliver the applicable Conversion Shares to Lender with a restricted securities
legend, but otherwise in accordance with the provisions of this Section 9. In conjunction therewith, Borrower will also deliver to Lender
a written explanation from its counsel or its transfer agent&rsquo;s counsel opining as to why the issuance of the applicable Conversion
Shares violates Rule 144.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">10. <U>Conversion
Delays</U>. If Borrower fails to deliver Conversion Shares in accordance with the timeframe stated in Section 9, Lender may at any
time prior to receiving the applicable Conversion Shares rescind in whole or in part such Conversion, with a corresponding increase
to the Outstanding Balance (any returned amount will tack back to the Purchase Price Date for purposes of determining the holding
period under Rule 144). In addition, for each Lender Conversion, in the event that Lender Conversion Shares are not delivered by the
sixth (6<SUP>th</SUP>) Trading Day (inclusive of the day of the Conversion), a late fee equal to 2% of the applicable Conversion
Share Value rounded to the nearest multiple of $100.00 (but in any event the cumulative amount of such late fees for each Conversion
shall not exceed the applicable Conversion Share Value) will be assessed for each day after the sixth (6<SUP>th</SUP>) Trading Day
(inclusive of the day of the Conversion) until Lender Conversion Share delivery is made (such fees, the &ldquo;<B>Conversion Delay
Late Fees</B>&rdquo;). Borrower will pay all Conversion Delay Late Fees via wire transfer of immediately available funds within
three (3) Trading Days of a demand from Lender. In the event Borrower fails to timely pay the accrued Conversion Delay Late Fees
following a demand from Lender, such Conversion Delay Late Fees will be added to the Outstanding Balance. Notwithstanding anything
herein to the contrary, on up to three (3) occasions Borrower shall have up to ten (10) Trading Days to deliver Lender Conversion
Shares without such delivery being considered late hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">11.
<U>Issuance Cap</U>. Notwithstanding anything to the contrary contained in this Note or the other Transaction Documents, Borrower and
Lender agree that the total cumulative number of shares of Common Stock issued to Lender hereunder together with all other Transaction
Documents may not exceed the requirements of NYSE American Company Guide Section 713(a) (&ldquo;<B>NYSE American 19.99% Cap</B>&rdquo;),
except that such limitation will not apply following Approval (defined below). If the number of shares of Common Stock issued to Lender
reaches the NYSE American 19.99% Cap, so as not to violate the 20% limit established in NYSE American Company Guide Section 713(a), Borrower
will use reasonable commercial efforts to obtain stockholder approval of the Note and the issuance of additional Conversion Shares, if
necessary, in accordance with the requirements of NYSE American Company Guide Section 713(a) (the &ldquo;<B>Approval</B>&rdquo;), and
until the Approval has been obtained, Lender shall not submit any Conversion Notice to the extent after giving effect to such conversion
would exceed the NYSE American 19.99% Cap. If Borrower is unable to obtain such Approval, any remaining Outstanding Balance of this Note
must be repaid in cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">12. <U>Restriction on
Equity Sales</U>. If at any time after the date that is one hundred twenty-one (121)&nbsp;&nbsp; days from the Purchase Price Date,
Borrower is unable to issue Common Stock to Lender as result of any lock-up or other agreement or restriction prohibiting the
issuance of Common Stock for a certain period of time, then the Outstanding Balance will automatically be increased by three percent
(3%) for each thirty (30)&nbsp;&nbsp; day period that Borrower is prohibited from issuing Common Stock (which increase shall be
pro-rated for any partial period). For the avoidance of doubt, such increase to the Outstanding Balance shall be in addition to all
other rights and remedies available to Lender under this Note and the other Transaction Documents and shall not be in lieu of, nor
deemed to be a waiver of any other rights or remedies available to Lender under this Note or any of the other Transaction Documents,
including without limitation calling a Trigger Event if Borrower fails to deliver Conversion Shares in accordance with the terms of
this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">13.
<U>Ownership Limitation</U>. Notwithstanding anything to the contrary contained in this Note or the other Transaction Documents, Borrower
shall not effect any conversion of this Note to the extent that after giving effect to such conversion would cause Lender (together with
its affiliates) to beneficially own a number of shares exceeding 4.99% of the number of shares of Common Stock outstanding on such date
(including for such purpose the Common Stock issuable upon such issuance) (the &ldquo;<B>Maximum Percentage</B>&rdquo;). For purposes
of this section, beneficial ownership of Common Stock will be determined pursuant to Section 13(d) of the 1934 Act. Notwithstanding the
forgoing, the term &ldquo;4.99%&rdquo; above shall be replaced with &ldquo;9.99%&rdquo; at such time as the Market Capitalization is less
than $10,000,000.00. Notwithstanding any other provision contained herein, if the term &ldquo;4.99%&rdquo; is replaced with &ldquo;9.99%&rdquo;
pursuant to the preceding sentence, such increase to &ldquo;9.99%&rdquo; shall remain at 9.99% until increased, decreased or waived by
Lender as set forth below. By written notice to Borrower, Lender may increase, decrease or waive the Maximum Percentage as to itself but
any such waiver will not be effective until the 61st day after delivery thereof. The foregoing 61-day notice requirement is enforceable,
unconditional and non-waivable and shall apply to all affiliates and assigns of Lender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in">14.
<U>Opinion of Counsel</U>. In the event that an opinion of counsel is needed for any matter related to this Note, Lender has the right
to have any such opinion provided by its counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">15.
<U>Governing Law; Venue</U>. This Note shall be construed and enforced in accordance with, and all questions concerning the construction,
validity, interpretation and performance of this Note shall be governed by, the internal laws of the State of New York, without giving
effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdiction) that would
cause the application of the laws of any jurisdiction other than the State of New York. The provisions set forth in the Purchase Agreement
to determine the proper venue for any disputes are incorporated herein by this reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">16.
<U>Arbitration of Disputes</U>. By its issuance or acceptance of this Note, each party agrees to be bound by the Arbitration Provisions
(as defined in the Purchase Agreement) set forth as an exhibit to the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in">17.
<U>Cancellation</U>. After repayment or conversion of the entire Outstanding Balance, this Note shall be deemed paid in full, shall automatically
be deemed canceled, and shall not be reissued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 0.5in">18.
<U>Amendments</U>. The prior written consent of both parties hereto shall be required for any change or amendment to this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">19.
<U>Assignments</U>. Borrower may not assign this Note without the prior written consent of Lender. This Note and any Common Stock issued
upon conversion of this Note may be offered, sold, assigned or transferred by Lender without the consent of Borrower, provided Lender
sends a 14-day prior written notice to Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">20.
<U>Notices</U>. Whenever notice is required to be given under this Note, unless otherwise provided herein, such notice shall be given
in accordance with the subsection of the Purchase Agreement titled &ldquo;Notices.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">21.
<U>Liquidated Damages</U>. Lender and Borrower agree that in the event Borrower fails to comply with any of the terms or provisions of
this Note, Lender&rsquo;s damages would be uncertain and difficult (if not impossible) to accurately estimate because of the parties&rsquo;
inability to predict future interest rates, future share prices, future trading volumes and other relevant factors. Accordingly, Lender
and Borrower agree that any fees, balance adjustments, Default Interest or other charges assessed under this Note are not penalties but
instead are intended by the parties to be, and shall be deemed, liquidated damages (under Lender&rsquo;s and Borrower&rsquo;s expectations
that any such liquidated damages will tack back to the Purchase Price Date for purposes of determining the holding period under Rule 144).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">22.
<U>Severability</U>. If any part of this Note is construed to be in violation of any law, such part shall be modified to achieve the objective
of Borrower and Lender to the fullest extent permitted by law and the balance of this Note shall remain in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>[Remainder of page intentionally left blank; signature
page follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">IN WITNESS WHEREOF, Borrower has caused this Note to be duly
executed as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">BORROWER:</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="font-variant: small-caps"><FONT STYLE="font-variant: small-caps"><B>CHINA PHARMA HOLDINGS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="padding-bottom: 1.5pt; width: 60%">&nbsp;</TD>
  <TD STYLE="padding-bottom: 1.5pt; width: 4%">By:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/ Zhilin Li</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>Zhilin Li, CEO</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2"><U>ACKNOWLEDGED, ACCEPTED AND AGREED:</U></TD>
  <TD>&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">&nbsp;</TD>
  <TD>&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">LENDER:</TD>
  <TD>&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">&nbsp;</TD>
  <TD>&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="font-variant: small-caps"><FONT STYLE="font-variant: small-caps"><B>STREETERVILLE CAPITAL, LLC</B></FONT></TD>
  <TD>&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">&nbsp;</TD>
  <TD>&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="padding-bottom: 1.5pt; width: 4%">By:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/ John M. Fife</TD>
  <TD STYLE="padding-bottom: 1.5pt; width: 60%">&nbsp;</TD>
  </TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>John M. Fife, President</TD>
  <TD>&nbsp;</TD>
  </TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[Signature Page to Convertible
promissory Note]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ATTACHMENT 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>DEFINITIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">For purposes of this Note, the following terms shall have
the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">A1. &ldquo;<B>Closing
Bid Price</B>&rdquo; and &ldquo;<B>Closing Trade Price</B>&rdquo; means the last closing bid price and last closing trade price, respectively,
for the Common Stock on its principal market, as reported by Bloomberg, or, if its principal market begins to operate on an extended hours
basis and does not designate the closing bid price or the closing trade price (as the case may be) then the last bid price or last trade
price, respectively, of the Common Stock prior to 4:00:00 p.m., New York time, as reported by Bloomberg, or, if its principal market is
not the principal securities exchange or trading market for the Common Stock, the last closing bid price or last trade price, respectively,
of the Common Stock on the principal securities exchange or trading market where the Common Stock is listed or traded as reported by Bloomberg,
or if the foregoing do not apply, the last closing bid price or last trade price, respectively, of the Common Stock in the over-the-counter
market on the electronic bulletin board for the Common Stock as reported by Bloomberg, or, if no closing bid price or last trade price,
respectively, is reported for the Common Stock by Bloomberg, the average of the bid prices, or the ask prices, respectively, of any market
makers for the Common Stock as reported by OTC Markets Group, Inc., and any successor thereto. If the Closing Bid Price or the Closing
Trade Price cannot be calculated for the Common Stock on a particular date on any of the foregoing bases, the Closing Bid Price or the
Closing Trade Price (as the case may be) of the Common Stock on such date shall be the fair market value as mutually determined by Lender
and Borrower. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other
similar transaction during such period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">A2. &ldquo;<B>Conversion</B>&rdquo;
means a Lender Conversion under Section 3 or a Redemption Conversion under Section 8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">A3. &ldquo;<B>Conversion
Share Value</B>&rdquo; means the product of the number of Lender Conversion Shares deliverable pursuant to any Lender Conversion Notice
multiplied by the Closing Trade Price of the Common Stock on the Delivery Date for such Lender Conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">A4. &ldquo;<B>Deemed
Issuance</B>&rdquo; means an issuance of Common Stock that shall be deemed to have occurred on the latest possible permitted date pursuant
to the terms hereof in the event Borrower fails to deliver Conversion Shares as and when required pursuant to Section 9 of this Note.
For the avoidance of doubt, if Borrower has elected or is deemed under Section 8.2 to have elected to pay a Redemption Amount in Redemption
Conversion Shares and fails to deliver such Redemption Conversion Shares, such failure shall be considered a Deemed Issuance hereunder
even if an Equity Conditions Failure exists at that time or other relevant date of determination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">A5. &ldquo;<B>DTC</B>&rdquo; means the Depository Trust
Company or any successor thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">A6. &ldquo;<B>DTC/FAST Program</B>&rdquo; means the DTC&rsquo;s
Fast Automated Securities Transfer program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">A7. &ldquo;<B>DWAC</B>&rdquo; means the DTC&rsquo;s Deposit/Withdrawal
at Custodian system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">A8. &ldquo;<B>DWAC
Eligible</B>&rdquo; means that (a) Borrower&rsquo;s Common Stock is eligible at DTC for full services pursuant to DTC&rsquo;s operational
arrangements, including without limitation transfer through DTC&rsquo;s DWAC system; (b) Borrower has been approved (without revocation)
by DTC&rsquo;s underwriting department; (c) Borrower&rsquo;s transfer agent is approved as an agent in the DTC/FAST Program; (d) the Conversion
Shares are otherwise eligible for delivery via DWAC; and (e) Borrower&rsquo;s transfer agent does not have a policy prohibiting or limiting
delivery of the Conversion Shares via DWAC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">A9. &ldquo;<B>Equity
Conditions Failure</B>&rdquo; means that any of the following conditions has not been satisfied on any given Redemption Date: (a) with
respect to the applicable date of determination all of the Conversion Shares would be freely tradable pursuant to an effective registration
statement, under Rule 144 or without the need for registration under any applicable federal or state securities laws (in each case, disregarding
any limitation on conversion of this Note); (b) no Trigger Event shall have occurred or be continuing hereunder; and (c) Borrower&rsquo;s
Common Stock is trading on NYSE American or Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Attachment 1 to Convertible Promissory Note, Page 1</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">A10. &ldquo;<B>Exempt
Issuance</B>&rdquo; means the issuance of (a) shares of Common Stock or options to employees, officers or directors of the Company pursuant
to any stock or option plan duly adopted for such purpose, by a majority of the non-employee members of the Board of Directors or a majority
of the members of a committee of non-employee directors established for such purpose for services rendered to the Company; (b) securities
exercisable or exchangeable for or convertible into shares of Common
Stock issued and outstanding on the date of this Agreement, provided that such securities have not been amended since the date of this
Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities
(other than in connection with stock splits or combinations) or to extend the term of such securities; and (c) securities issued pursuant
to acquisitions or strategic transactions approved by a majority of the disinterested directors of the Company, provided that such securities
are issued as &ldquo;restricted securities&rdquo; (as defined in Rule 144) and carry no registration rights that require or permit the
filing of any registration statement in connection therewith during the first 120 days from the Closing, and provided that any such issuance
shall only be to a Person (or to the equity holders of a Person) which is, itself or through its subsidiaries, an operating company or
an owner of an asset in a business synergistic with the current business of the Company at such time and shall provide to the Company
additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities
primarily for the purpose of raising capital or to an entity whose primary business is investing in securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">A11. &ldquo;<B>Fundamental
Transaction</B>&rdquo; means that (a) (i) Borrower or any of its subsidiaries shall, directly or indirectly, in one or more related transactions,
consolidate or merge with or into (whether or not Borrower or any of its subsidiaries is the surviving corporation) any other person or
entity (excluding any such transactions for the purpose of change of the Borrower&rsquo;s incorporation jurisdiction), or (ii) Borrower
or any of its subsidiaries shall, directly or indirectly, in one or more related transactions, sell, lease, license, assign, transfer,
convey or otherwise dispose of all or substantially all of its respective properties or assets to any other person or entity, or (iii)
Borrower or any of its subsidiaries shall, directly or indirectly, in one or more related transactions, allow any other person or entity
to make a purchase, tender or exchange offer that is accepted by the holders of more than 50% of the outstanding shares of voting stock
of Borrower (not including any shares of voting stock of Borrower held by the person or persons making or party to, or associated or affiliated
with the persons or entities making or party to, such purchase, tender or exchange offer), or (iv) Borrower or any of its subsidiaries
shall, directly or indirectly, in one or more related transactions, consummate a stock or share purchase agreement or other business combination
(including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement) with any other person or entity
whereby such other person or entity acquires more than 50% of the outstanding shares of voting stock of Borrower (not including any shares
of voting stock of Borrower held by the other persons or entities making or party to, or associated or affiliated with the other persons
or entities making or party to, such stock or share purchase agreement or other business combination), or (v) Borrower or any of its subsidiaries
shall, directly or indirectly, in one or more related transactions, reorganize, recapitalize or reclassify the Common Stock, other than
an increase in the number of authorized shares of Borrower&rsquo;s Common Stock, or (b) any &ldquo;person&rdquo; or &ldquo;group&rdquo;
(as these terms are used for purposes of Sections 13(d) and 14(d) of the 1934 Act and the rules and regulations promulgated thereunder)
is or shall become the &ldquo;beneficial owner&rdquo; (as defined in Rule 13d-3 under the 1934 Act), directly or indirectly, of 50% of
the aggregate ordinary voting power represented by issued and outstanding voting stock of Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">A12. &ldquo;<B>Lender Conversion Price</B>&rdquo; means
$1.50 from the Purchase Price Date until the date that is five (5)<FONT STYLE="font-size: 10pt">&nbsp; </FONT>months from the
Purchase Price Date and $3.00 thereafter, as may be adjusted pursuant to the terms set forth in this Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-size: 10pt">A13. &ldquo;<B>Major Trigger
Event</B>&rdquo; means any Trigger Event occurring under Sections 4.1(a), 4.1(c), 4.1(l), or 4.1(n).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">A14. &ldquo;<B>Mandatory
Default Amount</B>&rdquo; means the Outstanding Balance following the application of the Trigger Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">A15. &ldquo;<B>Market
Capitalization</B>&rdquo; means a number equal to (a) the average VWAP of the Common Stock for the immediately preceding fifteen (15)
Trading Days, multiplied by (b) the aggregate number of outstanding Common Stock as reported on Borrower&rsquo;s most recently filed Form
10-Q or Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Attachment 1 to Convertible Promissory Note, Page 2</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">A16. &ldquo;<B>Maximum Monthly Redemption Amount</B>&rdquo;
means $500,000.00 per calendar month.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">A17. &ldquo;<B>Minor Trigger Event</B>&rdquo; means any
Trigger Event that is not a Major Trigger Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">A18. &ldquo;<B>OID</B>&rdquo; means an original issue
discount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">A19.
&ldquo;<B>Other Agreements</B>&rdquo; means, collectively, (a) all existing and future agreements and instruments between, among or
by Borrower (or an affiliate), on the one hand, and Lender (or an affiliate), on the other hand, and (b) any financing agreement or
a material agreement that affects Borrower&rsquo;s ongoing business operations.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">A20. &ldquo;<B>Outstanding
Balance</B>&rdquo; means as of any date of determination, the Purchase Price, as reduced or increased, as the case may be, pursuant to
the terms hereof for payment, Conversion, offset, or otherwise, plus the OID, the Transaction Expense Amount, accrued but unpaid interest,
collection and enforcements costs (including attorneys&rsquo; fees) incurred by Lender, transfer, stamp, issuance and similar taxes and
fees related to Conversions, and any other fees or charges (including without limitation Conversion Delay Late Fees) incurred under this
Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">A21. &ldquo;<B>Purchase Price Date</B>&rdquo; means the
date the Purchase Price is delivered by Lender to Borrower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">A22. &ldquo;<B>Redemption
Conversion Price</B>&rdquo; means 85% multiplied by the average of the lowest VWAP during the ten (10) Trading Days immediately preceding
the applicable measurement date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">A23. &ldquo;<B>Trigger
Effect</B>&rdquo; means multiplying the Outstanding Balance as of the date the applicable Trigger Event occurred by (a) fifteen percent
(15%) for each occurrence of any Major Trigger Event, or (b) five percent (5%) for each occurrence of any Minor Trigger Event, and then
adding the resulting product to the Outstanding Balance as of the date the applicable Trigger Event occurred, with the sum of the foregoing
then becoming the Outstanding Balance under this Note as of the date the applicable Trigger Event occurred; provided that the Trigger
Effect may only be applied two (2) times hereunder with respect to Major Trigger Events and two (2) times hereunder with respect to Minor
Trigger Events; and provided further that the Trigger Effect shall not apply to any Trigger Event pursuant to Section 4.1(b) hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">A24. &ldquo;<B>Trading Day</B>&rdquo; means any day on
which Borrower&rsquo;s principal market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">A25. &ldquo;<B>VWAP</B>&rdquo;
means the volume weighted average price of the Common Stock on the principal market for a particular Trading Day or set of Trading Days,
as the case may be, as reported by Bloomberg.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>[Remainder of page intentionally left blank]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Attachment 1 to Convertible Promissory Note, Page 3</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Streeterville Capital, LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">303 East Wacker Drive, Suite 1040</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chicago, Illinois 60601</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">China Pharma Holdings, Inc.</FONT></TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 20%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date:
                                            _______________</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Zhilin Li</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second
Floor, No. 17, Jinpan Road</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Haikou,
Hainan Province 570216</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LENDER
CONVERSION NOTICE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The above-captioned Lender hereby gives
notice to China Pharma Holdings, Inc., a Nevada corporation (the &ldquo;<B>Borrower</B>&rdquo;), pursuant to that certain Convertible
Promissory Note made by Borrower in favor of Lender on November 17, 2021 (the &ldquo;<B>Note</B>&rdquo;), that Lender elects to convert
the portion of the Note balance set forth below into fully paid and non-assessable Common Stock of Borrower as of the date of conversion
specified below. Said conversion shall be based on the Lender Conversion Price set forth below. In the event of a conflict between this
Lender Conversion Notice and the Note, the Note shall govern, or, in the alternative, at the election of Lender in its sole discretion,
Lender may provide a new form of Lender Conversion Notice to conform to the Note. Capitalized terms used in this notice without definition
shall have the meanings given to them in the Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.7pt"></TD><TD STYLE="width: 22.3pt">A.</TD><TD>Date of Conversion: ____________</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 22.5pt">B.</TD><TD>Lender Conversion #: ____________</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 22.5pt">C.</TD><TD>Conversion Amount: ____________</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 22.5pt">D.</TD><TD>Lender Conversion Price: _______________</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 22.5pt">E.</TD><TD>Lender Conversion Shares: _______________ (C divided by D)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 22.5pt">F.</TD><TD>Remaining Outstanding Balance of Note: ____________*</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">Subject to adjustments for corrections, defaults, interest and
other adjustments permitted by the Transaction Documents (as defined in the Purchase Agreement), the terms of which shall control in
the event of any dispute between the terms of this Lender Conversion Notice and such Transaction Documents.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Please transfer the Lender Conversion Shares electronically (via
DWAC) to the following account</I></B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 57%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broker:
    ___________________________________</FONT></TD>
    <TD STYLE="width: 12%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="width: 31%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DTC#:</FONT> ___________________________________</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Account #:</FONT> _______________________________</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Account Name:</FONT> ____________________________</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">To the extent the
Lender Conversion Shares are not able to be delivered to Lender electronically via the DWAC system, deliver all such certificated shares
to Lender via reputable overnight courier after receipt of this Lender Conversion Notice (by facsimile transmission or otherwise) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">_____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">_____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">_____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>[Signature Page Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A to Convertible Promissory Note, Page 1</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Sincerely,</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Lender:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-variant: small-caps; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>S<FONT STYLE="font-size: 10pt">TREETERVILLE </FONT>C<FONT STYLE="font-size: 10pt">APITAL</FONT>, LLC</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; width: 36%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">John M. Fife, President</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit A to Convertible Promissory Note, Page 2</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXHIBIT
B</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Streeterville Capital, LLC</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">303 East Wacker Drive, Suite 1040</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chicago, Illinois 60601</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 80%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">China
                           Pharma Holdings, Inc.</FONT></TD><TD STYLE="text-align: justify; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: _______________</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Zhilin Li</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second
Floor, No. 17, Jinpan Road</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Haikou,
Hainan Province 570216</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>REDEMPTION NOTICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The above-captioned Lender hereby gives
notice to China Pharma Holdings, Inc., a Nevada corporation (the &ldquo;<B>Borrower</B>&rdquo;), pursuant to that certain Convertible
Promissory Note made by Borrower in favor of Lender on November 17, 2021 (the &ldquo;<B>Note</B>&rdquo;), that Lender elects to redeem
a portion of the Note in Redemption Conversion Shares or in cash as set forth below. In the event of a conflict between this Redemption
Notice and the Note, the Note shall govern, or, in the alternative, at the election of Lender in its sole discretion, Lender may provide
a new form of Redemption Notice to conform to the Note. Capitalized terms used in this notice without definition shall have the meanings
given to them in the Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B><U>REDEMPTION INFORMATION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 22.5pt">A.</TD><TD>Redemption Date: ____________, 201_</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 22.5pt">B.</TD><TD>Redemption Amount: ____________</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 22.5pt">C.</TD><TD>Portion of Redemption Amount to be Paid in Cash: ____________</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 22.5pt">D.</TD><TD>Portion of Redemption Amount to be Converted into Common Stock: ____________ (B minus C)</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 22.5pt">E.</TD><TD>Redemption Conversion Price: _______________</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 22.5pt">F.</TD><TD>Redemption Conversion Shares: _______________ (D divided by E)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 13.5pt"></TD><TD STYLE="width: 22.5pt">G.</TD><TD>Remaining Outstanding Balance of Note: ____________ *</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">Subject to adjustments for corrections, defaults, interest and
other adjustments permitted by the Transaction Documents (as defined in the Purchase Agreement), the terms of which shall control in
the event of any dispute between the terms of this Redemption Notice and such Transaction Documents.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><B><I>Please transfer the Redemption
Conversion Shares, if applicable, electronically (via DWAC) to the following account</I></B>:</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 57%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broker:
    ___________________________________</FONT></TD>
    <TD STYLE="width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address:</FONT></TD>
    <TD STYLE="width: 28%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DTC#:</FONT> ___________________________________</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Account #:</FONT> _______________________________</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Account Name:</FONT> ____________________________</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">To the extent the
Redemption Conversion Shares are not able to be delivered to Lender electronically via the DWAC system, deliver all such certificated
shares to Lender via reputable overnight courier after receipt of this Redemption Notice (by facsimile transmission or otherwise) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">_____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">_____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">_____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit B to Convertible Promissory Note, Page 1</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Sincerely,</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Lender:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-variant: small-caps; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>S<FONT STYLE="font-size: 10pt">TREETERVILLE </FONT>C<FONT STYLE="font-size: 10pt">APITAL</FONT>, LLC</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; width: 36%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">John M. Fife, President</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Exhibit B to Convertible Promissory Note,
Page 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 297pt"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>ea151262ex10-1_chinapharma.htm
<DESCRIPTION>SECURITIES PURCHASE AGREEMENT BETWEEN CHINA PHARMA HOLDINGS, INC. AND STREETERVILLE CAPITAL, LLC DATED NOVEMBER 17, 2021
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-variant: small-caps">Securities
Purchase Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">THIS SECURITIES PURCHASE
AGREEMENT (this &ldquo;<B>Agreement</B>&rdquo;), dated as of November 17, 2021, is entered into by and between CHINA PHARMA HOLDINGS,
INC., a Nevada corporation (&ldquo;<B>Company</B>&rdquo;), and STREETERVILLE CAPITAL, LLC, a Utah limited liability company, its successors
and/or assigns (&ldquo;<B>Investor</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">A. Company
and Investor are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by the Securities
Act of 1933, as amended (the &ldquo;<B>1933 Act</B>&rdquo;), and the rules and regulations promulgated thereunder by the United States
Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">B. Investor desires
to purchase and Company desires to issue and sell, upon the terms and conditions set forth in this Agreement a Convertible Promissory
Note, in the form attached hereto as <U>Exhibit A</U>, in the original principal amount of $5,250,000.00 (the &ldquo;<B>Note</B>&rdquo;),
convertible into shares of common stock, $0.001 par value per share, of Company (the &ldquo;<B>Common Stock</B>&rdquo;), upon the terms
and subject to the limitations and conditions set forth in such Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">C. This
Agreement, the Note, and all other certificates, documents, agreements, resolutions and instruments delivered to any party under or in
connection with this Agreement, as the same may be amended from time to time, are collectively referred to herein as the &ldquo;<B>Transaction
Documents</B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">D. For
purposes of this Agreement: &ldquo;<B>Conversion Shares</B>&rdquo; means all shares of Common Stock issuable upon conversion of all or
any portion of the Note; and &ldquo;<B>Securities</B>&rdquo; means the Note and the Conversion Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>,
in consideration of the above recitals and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
Company and Investor hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> 1. <U>Purchase and Sale of Securities</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">1.1. <U>Purchase of
Securities</U>. Company shall issue and sell to Investor and Investor shall purchase from Company the Note. In consideration thereof,
Investor shall pay the Purchase Price (as defined below) to Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">1.2. <U>Form of Payment</U>.
On the Closing Date (as defined below), Investor shall pay the Purchase Price to Company via wire transfer of immediately available funds
against delivery of the Note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">1.3. <U>Closing Date</U>.
Subject to the satisfaction (or written waiver) of the conditions set forth in Section 5 and Section 6 below, the date of the issuance
and sale of the Note pursuant to this Agreement (the &ldquo;<B>Closing Date</B>&rdquo;) shall be November 17, 2021, or another mutually
agreed upon date. The closing of the transactions contemplated by this Agreement (the &ldquo;<B>Closing</B>&rdquo;) shall occur on the
Closing Date by means of the exchange by email of signed .pdf documents, but shall be deemed for all purposes to have occurred at the
offices of Hansen Black Anderson Ashcraft PLLC in Lehi, Utah.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">1.4.</FONT> <FONT STYLE="font-size: 10pt"><U>Collateral
for the Note</U>. The Note shall be unsecured.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">1.5. <U>Original
Issue Discount; Transaction Expense Amount</U>. The Note carries an original issue discount of $250,000.00 (the
&ldquo;<B>OID</B>&rdquo;), which amount is included in the initial principal balance of the Note. In addition, Company agrees to pay
$15,000.00 to Investor to cover Investor&rsquo;s legal fees, accounting costs, due diligence, monitoring and other transaction
costs incurred in connection with the purchase and sale of the Securities (the &ldquo;<B>Transaction Expense Amount</B>&rdquo;),
which amount is excluded in the initial principal balance of the Note. The &ldquo;<B>Purchase Price</B>&rdquo;, therefore, shall be
$5,000,000.00, computed as follows: $5,250,000.00 initial principal balance, less the OID. The Transaction Expense Amount will be
deducted from the amount funded at Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">2. <U>Investor&rsquo;s
Representations and Warranties</U>. Investor represents and warrants to Company that as of the Closing Date: (i) this Agreement has been
duly and validly authorized; (ii) this Agreement constitutes a valid and binding agreement of Investor enforceable in accordance with
its terms; and (iii) Investor is an &ldquo;accredited investor&rdquo; as that term is defined in Rule 501(a) of Regulation D of the 1933
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">3. <U>Company&rsquo;s
Representations and Warranties</U>. Company represents and warrants to Investor that as of the Closing Date: (i) Company is a
corporation duly organized, validly existing and in good standing under the laws of its state of incorporation and has the requisite
corporate power to own its properties and to carry on its business as now being conducted; (ii) Company is duly qualified as a
foreign corporation to do business and is in good standing in each jurisdiction where the nature of the business conducted or
property owned by it makes such qualification necessary; (iii) Company has registered its Common Stock under Section 12(g) of the
Securities Exchange Act of 1934, as amended (the &ldquo;<B>1934 Act</B>&rdquo;), and is obligated to file reports pursuant to
Section 13 or Section 15(d) of the 1934 Act; (iv) each of the Transaction Documents and the transactions contemplated hereby and
thereby, have been duly and validly authorized by Company and all necessary actions have been taken; (v) this Agreement, the Note,
and the other Transaction Documents have been duly executed and delivered by Company and constitute the valid and binding
obligations of Company enforceable in accordance with their terms; (vi) the execution and delivery of the Transaction Documents by
Company, the issuance of Securities in accordance with the terms hereof, and the consummation by Company of the other transactions
contemplated by the Transaction Documents do not and will not conflict with or result in a breach by Company of any of the terms or
provisions of, or constitute a default under (a) Company&rsquo;s formation documents or bylaws, each as currently in effect, (b) any
indenture, mortgage, deed of trust, or other material agreement or instrument to which Company is a party or by which it or any of
its properties or assets are bound, including, without limitation, any listing agreement for the Common Stock, or (c) any existing
applicable law, rule, or regulation or any applicable decree, judgment, or order of any court, United States federal, state or
foreign regulatory body, administrative agency, or other governmental body having jurisdiction over Company or any of
Company&rsquo;s properties or assets; (vii) no further authorization, approval or consent of any court, governmental body,
regulatory agency, self-regulatory organization, or stock exchange or market or the stockholders or any lender of Company is
required to be obtained by Company for the issuance of the Securities to Investor or the entering into of the Transaction Documents;
(viii) none of Company&rsquo;s filings with the SEC contained, at the time they were filed, any untrue statement of a material fact
or omitted to state any material fact required to be stated therein or necessary to make the statements made therein, in light of
the circumstances under which they were made, not misleading; (ix) Company has filed all reports, schedules, forms, statements and
other documents required to be filed by Company with the SEC under the 1934 Act on a timely basis or has received a valid extension
of such time of filing and has filed any such report, schedule, form, statement or other document prior to the expiration of any
such extension; (x) there is no action, suit, proceeding, inquiry or investigation before or by any court, public board or body
pending or, to the knowledge of Company, threatened against or affecting Company before or by any governmental authority or
non-governmental department, commission, board, bureau, agency or instrumentality or any other person, wherein an unfavorable
decision, ruling or finding would have a material adverse effect on Company or which would adversely affect the validity or
enforceability of, or the authority or ability of Company to perform its obligations under, any of the Transaction Documents; (xi)
Company has not consummated any financing transaction that has not been disclosed in a periodic filing or current report with the
SEC under the 1934 Act; (xii) Company is not, nor has it been at any time in the previous twelve (12) months, a &ldquo;Shell
Company,&rdquo; as such type of &ldquo;issuer&rdquo; is described in Rule 144(i)(1) under the 1933 Act; (xiii) with respect to any
commissions, placement agent or finder&rsquo;s fees or similar payments that will or would become due and owing by Company to any
person or entity as a result of this Agreement or the transactions contemplated hereby (&ldquo;<B>Broker Fees</B>&rdquo;), any such
Broker Fees will be made in full compliance with all applicable laws and regulations and only to a person or entity that is a
registered investment adviser or registered broker-dealer; (xiv) Investor shall have no obligation with respect to any Broker Fees
or with respect to any claims made by or on behalf of other persons for fees of a type contemplated in this subsection that may be
due in connection with the transactions contemplated hereby and Company shall indemnify and hold harmless each of Investor,
Investor&rsquo;s employees, officers, directors, stockholders, members, managers, agents, and partners, and their respective
affiliates, from and against all claims, losses, damages, costs (including the costs of preparation and attorneys&rsquo; fees) and
expenses suffered in respect of any such claimed Broker Fees; (xv) neither Investor nor any of its officers, directors,
stockholders, members, managers, employees, agents or representatives has made any representations or warranties to Company or any
of its officers, directors, employees, agents or representatives except as expressly set forth in the Transaction Documents and, in
making its decision to enter into the transactions contemplated by the Transaction Documents, Company is not relying on any
representation, warranty, covenant or promise of Investor or its officers, directors, members, managers, employees, agents or
representatives other than as set forth in the Transaction Documents; (xvi) Company acknowledges that the State of Utah has a
reasonable relationship and sufficient contacts to the transactions contemplated by the Transaction Documents and any dispute that
may arise related thereto such that the laws and venue of the State of Utah, as set forth more specifically in Section 9.2 below,
shall be applicable to the Transaction Documents and the transactions contemplated therein; and (xvii) Company has performed due
diligence and background research on Investor and its affiliates including, without limitation, John M. Fife, and, to its
satisfaction, has made inquiries with respect to all matters Company may consider relevant to the undertakings and relationships
contemplated by the Transaction Documents including, among other things, the following:
http://investing.businessweek.com/research/stocks/people/person.asp?personId=7505107&amp;ticker=UAHC; SEC Civil Case No. 07-C-0347
(N.D. Ill.); SEC Civil Action No. 07-CV-347 (N.D. Ill.); and FINRA Case #2011029203701. In addition, various affiliates of Investor
are involved in ongoing litigation with the SEC regarding broker-dealer registration (<I>see</I> SEC Civil Case No. 1:20-cv-05227
(N.D. Ill.)). Company, being aware of the matters described in subsection (xvii) above, acknowledges and agrees that such matters,
or any similar matters, have no bearing on the transactions contemplated by the Transaction Documents and covenants and agrees it
will not use any such information as a defense to performance of its obligations under the Transaction Documents or in any attempt
to avoid, modify or reduce such obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">4. <U>Company
Covenants</U>. Until all of Company&rsquo;s obligations under all of the Transaction Documents are paid and performed in full, or
within the timeframes otherwise specifically set forth below, Company will at all times comply with the following covenants: (i) so
long as Investor beneficially owns any of the Securities and for at least twenty (20) Trading Days (as defined in the Note)
thereafter, Company will timely file on the applicable deadline all reports required to be filed with the SEC pursuant to Sections
13 or 15(d) of the 1934 Act, and will take all reasonable action under its control to ensure that adequate current public
information with respect to Company, as required in accordance with Rule 144 of the 1933 Act, is publicly available, and will not
terminate its status as an issuer required to file reports under the 1934 Act even if the 1934 Act or the rules and regulations
thereunder would permit such termination; (ii) when issued, the Conversion Shares will be duly authorized, validly issued, fully
paid for and non-assessable, free and clear of all liens, claims, charges and encumbrances; (iii) the Common Stock shall be listed
or quoted for trading on NYSE American or Nasdaq; (iv) trading in Company&rsquo;s Common Stock will not be suspended, halted,
chilled, frozen, reach zero bid or otherwise cease trading on Company&rsquo;s principal trading market; (v) until such time as the
Note has been repaid in full and Investor holds no Conversion Shares (as defined in the Note), Company will not make any Variable
Security Issuances (as defined below) without Investor&rsquo;s prior written consent, which consent may be granted or withheld in
Investor&rsquo;s sole and absolute discretion; (vi) within thirty (30) days following Closing, Company will file a Prospectus
Supplement pursuant to Rule 424(b)(5) to allocate $5,000,000.00 of its S-3 shelf registration statement (No. 333-251973) for the
issuance of Conversion Shares to Investor under the Note; and (vii) Company will not enter into any agreement that limits
Company&rsquo;s right to issue shares of Common Stock to Investor under the Note. For purposes hereof, the term &ldquo;<B>Variable
Security Issuance</B>&rdquo; means any issuance of any Company securities that (A) have or may have conversion rights of any kind,
contingent, conditional or otherwise, in which the number of shares that may be issued pursuant to such conversion right varies with
the market price of the Common Stock, or (B) are or may become convertible into Common Stock (including without limitation
convertible debt, warrants or convertible preferred stock), with a conversion price that varies with the market price of the Common
Stock, even if such security only becomes convertible following an event of default, the passage of time, or another trigger event
or condition. For avoidance of doubt, the issuance of shares of Common Stock under, pursuant to, in exchange for or in connection
with any contract or instrument, whether convertible or not, is deemed a Variable Security Issuance for purposes hereof if the
number of shares of Common Stock to be issued is based upon or related in any way to the market price of the Common Stock,
including, but not limited to, Common Stock issued in connection with a Section 3(a)(9) exchange, a Section 3(a)(10) settlement, or
any other similar settlement or exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">5. <U>Conditions
to Company&rsquo;s Obligation to Sell</U>. The obligation of Company hereunder to issue and sell the Securities to Investor at the Closing
is subject to the satisfaction, on or before the Closing Date, of each of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">5.1.</FONT> <FONT STYLE="font-size: 10pt">Investor
shall have executed this Agreement and delivered the same to Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-indent: 1in">5.2. Investor shall have delivered the Purchase
Price to Company in accordance with Section 1.2 above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">6. <U>Conditions
to Investor&rsquo;s Obligation to Purchase</U>. The obligation of Investor hereunder to purchase the Securities at the Closing is subject
to the satisfaction, on or before the Closing Date, of each of the following conditions, provided that these conditions are for Investor&rsquo;s
sole benefit and may be waived by Investor at any time in its sole discretion:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><FONT STYLE="font-size: 10pt">6.1. Company shall have executed
this Agreement and the Note and delivered the same</FONT> to Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">6.2. Company shall
have delivered to Investor a fully executed Irrevocable Letter of Instructions to Transfer Agent (the &ldquo;<B>TA Letter</B>&rdquo;)
substantially in the form attached hereto as <U>Exhibit B</U> acknowledged and agreed to in writing by Company&rsquo;s transfer agent
(the &ldquo;<B>Transfer Agent</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">6.3. Company shall
have delivered to Investor a fully executed Secretary&rsquo;s Certificate substantially in the form attached hereto as <U>Exhibit C</U>
evidencing Company&rsquo;s approval of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">6.4. Company shall
have delivered to Investor a fully executed Share Issuance Resolution substantially in the form attached hereto as <U>Exhibit D</U> to
be delivered to the Transfer Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">6.5. Company shall
have delivered to Investor fully executed copies of all other Transaction Documents required to be executed by Company herein or therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">7. <U>Reservation
of Shares</U>. On the date hereof, Company will reserve 30,000,000 shares of Common Stock from its authorized and unissued Common Stock
to provide for all issuances of Common Stock under the Note (the &ldquo;<B>Share Reserve</B>&rdquo;). Company further agrees to add additional
shares of Common Stock to the Share Reserve in increments of 1,000,000 shares as and when requested by Investor if as of the date of
any such request the number of shares being held in the Share Reserve is less than three (3) times the number of shares of Common
Stock obtained by dividing the Outstanding Balance (as defined in the Note) as of the date of the request by the lower of the Lender
Conversion Price (as defined in the Note) and the Redemption Conversion Price (as defined in the Note). Company shall further require
the Transfer Agent to hold the shares of Common Stock reserved pursuant to the Share Reserve exclusively for the benefit of Investor
and to issue such shares to Investor promptly upon Investor&rsquo;s delivery of a Redemption Notice that Company elects to pay in Conversion
Shares or a Lender Conversion Notice under the Note. Finally, Company shall require the Transfer Agent to issue shares of Common Stock
pursuant to the Note to Investor out of its authorized and unissued shares, and not the Share Reserve, to the extent shares of Common
Stock have been authorized, but not issued, and are not included in the Share Reserve. The Transfer Agent shall only issue shares out
of the Share Reserve to the extent there are no other authorized shares available for issuance and then only with Investor&rsquo;s written
consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt"> 8. <U>OFAC; Patriot Act</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">8.1. <U>OFAC Certification</U>.
Company certifies that (i) it is not acting on behalf of any person, group, entity, or nation named by any Executive Order or the United
States Treasury Department, through its Office of Foreign Assets Control (&ldquo;<B>OFAC</B>&rdquo;) or otherwise, as a terrorist, &ldquo;Specially
Designated Nation&rdquo;, &ldquo;Blocked Person&rdquo;, or other banned or blocked person, entity, nation, or transaction pursuant to
any law, order, rule or regulation that is enforced or administered by OFAC or another department of the United States government, and
(ii) Company is not engaged in this transaction on behalf of, or instigating or facilitating this transaction on behalf of, any such person,
group, entity or nation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">8.2. <U>Foreign Corrupt
Practices</U>. Neither Company, nor any of its subsidiaries, nor any director, officer, agent, employee or other person acting on behalf
of Company or any subsidiary has, in the course of his actions for, or on behalf of, Company, used any corporate funds for any unlawful
contribution, gift, entertainment or other unlawful expenses relating to political activity; made any direct or indirect unlawful payment
to any foreign or domestic government official or employee from corporate funds; violated or is in violation of any provision of the U.S.
Foreign Corrupt Practices Act of 1977, as amended, or made any bribe, rebate, payoff, influence payment, kickback or other unlawful payment
to any foreign or domestic government official or employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">8.3. <U>Patriot Act</U>.
Company shall not (i) be or become subject at any time to any law, regulation, or list of any government agency (including, without limitation,
the OFAC) that prohibits or limits Investor from making any advance or extension of credit to Company or from otherwise conducting business
with Company, or (ii) fail to provide documentary and other evidence of Company&rsquo;s identity as may be requested by Investor at any
time to enable Investor to verify Company&rsquo;s identity or to comply with any applicable law or regulation, including, without limitation,
Section 326 of the USA Patriot Act of 2001, 31 U.S.C. Section 5318. Company shall comply with all requirements of law relating to money
laundering, anti-terrorism, trade embargos and economic sanctions, now or hereafter in effect. Upon Investor&rsquo;s request from time
to time, Company shall certify in writing to Investor that Company&rsquo;s representations, warranties and obligations under this Section
8.3 remain true and correct and have not been breached. Company shall immediately notify Investor in writing if any of such representations,
warranties or covenants are no longer true or have been breached or if Company has a reasonable basis to believe that they may no longer
be true or have been breached. In connection with such an event, Company shall comply with all requirements of law and directives of governmental
authorities and, at Investor&rsquo;s request, provide to Investor copies of all notices, reports and other communications exchanged with,
or received from, governmental authorities relating to such an event. Company shall also reimburse Investor any expense incurred by Investor
in evaluating the effect of such an event on the loan secured hereby, in obtaining any necessary license from governmental authorities
as may be necessary for Investor to enforce its rights under the Transaction Documents, and in complying with all requirements of law
applicable to Investor as the result of the existence of such an event and for any penalties or fines imposed upon Investor as a result
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in">9. <U>Miscellaneous</U>.
The provisions set forth in this Section 9 shall apply to this Agreement, as well as all other Transaction Documents as if these terms
were fully set forth therein; provided, however, that in the event there is a conflict between any provision set forth in this Section
9 and any provision in any other Transaction Document, the provision in such other Transaction Document shall govern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">9.1. <U>Arbitration
of Claims</U>. The parties shall submit all Claims (as defined in <U>Exhibit E</U>) arising under this Agreement or any other Transaction
Document or any other agreement between the parties and their affiliates or any Claim relating to the relationship of the parties to
binding arbitration pursuant to the arbitration provisions set forth in <U>Exhibit E</U> attached hereto (the &ldquo;<B>Arbitration Provisions</B>&rdquo;).
For the avoidance of doubt, the parties agree that the injunction described in Section 9.3 below may be pursued in an arbitration that
is separate and apart from any other arbitration regarding all other Claims arising under the Transaction Documents. The parties hereby
acknowledge and agree that the Arbitration Provisions are binding on the parties hereto and are severable from all other provisions of
this Agreement. By executing this Agreement, Company represents, warrants and covenants that Company has reviewed the Arbitration Provisions
carefully, consulted with legal counsel about such provisions (or waived its right to do so), understands that the Arbitration Provisions
are intended to allow for the expeditious and efficient resolution of any dispute hereunder, agrees to the terms and limitations set
forth in the Arbitration Provisions, and that Company will not take a position contrary to the foregoing representations. Company acknowledges
and agrees that Investor may rely upon the foregoing representations and covenants of Company regarding the Arbitration Provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">9.2. <U>Governing
Law; Venue</U>. This Agreement shall be construed and enforced in accordance with, and all questions concerning the construction,
validity, interpretation and performance of this Agreement shall be governed by, the internal laws of the State of New York, without
giving effect to any choice of law or conflict of law provision or rule (whether of the State of New York or any other jurisdiction)
that would cause the application of the laws of any jurisdiction other than the State of New York. Each party consents to and
expressly agrees that the exclusive venue and arbitral seat for arbitration of any dispute arising out of or relating to any
Transaction Document or the relationship of the parties or their affiliates shall be in Salt Lake County, Utah; <I>provided,
however</I>, that a virtual attendance option will be provided for all hearings. Without modifying the parties&rsquo; obligations to
resolve disputes hereunder pursuant to the Arbitration Provisions, for any litigation arising in connection with any of the
Transaction Documents (and notwithstanding the terms (specifically including any governing law and venue terms) of any transfer
agent services agreement or other agreement between the Transfer Agent and Company, such litigation specifically includes, without
limitation any action between or involving Company and the Transfer Agent under the TA Letter or otherwise related to Investor in
any way (specifically including, without limitation, any action where Company seeks to obtain an injunction, temporary restraining
order, or otherwise prohibit the Transfer Agent from issuing shares of Common Stock to Investor for any reason)), each party hereto
hereby (i) consents to and expressly submits to the exclusive personal jurisdiction of any state or federal court sitting in Salt
Lake County, Utah, (ii) expressly submits to the exclusive venue of any such court for the purposes hereof, (iii) agrees to not
bring any such action (specifically including, without limitation, any action where Company seeks to obtain an injunction, temporary
restraining order, or otherwise prohibit the Transfer Agent from issuing shares of Common Stock to Investor for any reason) outside
of any state or federal court sitting in Salt Lake County, Utah, and (iv) waives any claim of improper venue and any claim or
objection that such courts are an inconvenient forum or any other claim, defense or objection to the bringing of any such proceeding
in such jurisdiction or to any claim that such venue of the suit, action or proceeding is improper. Finally, Company covenants and
agrees to name Investor as a party in interest in, and provide written notice to Investor in accordance with Section 9.9 below prior
to bringing or filing, any action (including without limitation any filing or action against any person or entity that is not a
party to this Agreement, including without limitation the Transfer Agent) that is related in any way to the Transaction Documents or
any transaction contemplated herein or therein, including without limitation any action brought by Company to enjoin or prevent the
issuance of any shares of Common Stock to Investor by the Transfer Agent, and further agrees to timely name Investor as a
party to any such action. Company acknowledges that the governing law and venue provisions set forth in this Section 9.2 are
material terms to induce Investor to enter into the Transaction Documents and that but for Company&rsquo;s agreements set forth in
this Section 9.2 Investor would not have entered into the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">9.3. <U>Specific Performance</U>.
Company acknowledges and agrees that Investor may suffer irreparable harm in the event that Company fails to perform any material provision
of this Agreement or any of the other Transaction Documents in accordance with its specific terms. It is accordingly agreed that Investor
shall be entitled to one or more injunctions to prevent or cure breaches of the provisions of this Agreement or such other Transaction
Document and to enforce specifically the terms and provisions hereof or thereof, this being in addition to any other remedy to which the
Investor may be entitled under the Transaction Documents, at law or in equity. Company specifically agrees that following an Event of
Default (as defined in the Note) under the Note, Investor shall have the right to seek and receive injunctive relief from a court or an
arbitrator prohibiting Company from issuing any of its common or preferred stock to any party unless the Note is being paid in full simultaneously
with such issuance. Company specifically acknowledges that Investor&rsquo;s right to obtain specific performance constitutes bargained
for leverage and that the loss of such leverage would result in irreparable harm to Investor. For the avoidance of doubt, in the event
Investor seeks to obtain an injunction from a court or an arbitrator against Company or specific performance of any provision of any Transaction
Document, such action shall not be a waiver of any right of Investor under any Transaction Document, at law, or in equity, including without
limitation its rights to arbitrate any Claim pursuant to the terms of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">9.4. <U>Counterparts</U>.
Each Transaction Document may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together
shall constitute one instrument. The parties hereto confirm that any electronic copy of another party&rsquo;s executed counterpart of
a Transaction Document (or such party&rsquo;s signature page thereof) will be deemed to be an executed original thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">9.5. <U>Headings</U>.
The headings of this Agreement are for convenience of reference only and shall not form part of, or affect the interpretation of, this
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">9.6. <U>Severability</U>.
In the event that any provision of this Agreement is invalid or unenforceable under any applicable statute or rule of law, then such provision
shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform to such statute or rule
of law. Any provision hereof which may prove invalid or unenforceable under any law shall not affect the validity or enforceability of
any other provision hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">9.7. <U>Entire Agreement</U>.
This Agreement, together with the other Transaction Documents, contains the entire understanding of the parties with respect to the matters
covered herein and therein and, except as specifically set forth herein or therein, neither Company nor Investor makes any representation,
warranty, covenant or undertaking with respect to such matters. For the avoidance of doubt, all prior term sheets or other documents between
Company and Investor, or any affiliate thereof, related to the transactions contemplated by the Transaction Documents (collectively, &ldquo;<B>Prior
Agreements</B>&rdquo;), that may have been entered into between Company and Investor, or any affiliate thereof, are hereby null and void
and deemed to be replaced in their entirety by the Transaction Documents. To the extent there is a conflict between any term set forth
in any Prior Agreement and the term(s) of the Transaction Documents, the Transaction Documents shall govern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">9.8. <U>Amendments</U>.
No provision of this Agreement may be waived or amended other than by an instrument in writing signed by both parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">9.9. <U>Notices</U>.
Any notice required or permitted hereunder shall be given in writing (unless otherwise specified herein) and shall be deemed effectively
given on the earliest of: (i) the date delivered, if delivered by personal delivery as against written receipt therefor or by email to
an executive officer named below or such officer&rsquo;s successor, or by facsimile (with successful transmission confirmation which is
kept by sending party), (ii) the earlier of the date delivered or the tenth Trading Day after deposit, postage prepaid, with an international
courier, or (iii) the earlier of the date delivered or the third Trading Day after mailing by express courier, with delivery costs and
fees prepaid, in each case, addressed to each of the other parties thereunto entitled at the following addresses (or at such other addresses
as such party may designate by five (5) calendar days&rsquo; advance written notice similarly given to each of the other parties hereto):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 57pt">If to Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">China Pharma Holdings, Inc.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attn: Zhilin Li</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Second Floor, No. 17, Jinpan Road</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Haikou, Hainan Province 570216</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">China</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">hps@chinapharmaholdings.com&gt;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 57pt">With a copy to (which copy shall not constitute notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Pryor Cashman LLP&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attn: Elizabeth Fei Chen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">7 Times Square, New York, NY 10036</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">echen@pryorcashman.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 57pt">If to Investor:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Streeterville Capital, LLC&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attn: John Fife</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">303 East Wacker Drive, Suite 1040</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Chicago, Illinois 60601</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">jfife@chicagoventure.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 57pt">With a copy to (which copy shall not constitute notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Hansen Black Anderson Ashcraft PLLC&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Attn: Jonathan Hansen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">3051 West Maple Loop Drive, Suite 325</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Lehi, Utah 84043</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">jhansen@hbaa.law</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">9.10. <U>Successors
and Assigns</U>. This Agreement or any of the severable rights and obligations inuring to the benefit of or to be performed by Investor
hereunder may be assigned by Investor to a third party, including its affiliates, in whole or in part, without the need to obtain Company&rsquo;s
consent thereto. Company may not assign its rights or obligations under this Agreement or delegate its duties hereunder, whether directly
or indirectly, without the prior written consent of Investor, and any such attempted assignment or delegation shall be null and void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">9.11. <U>Survival</U>.
The representations and warranties of Company and the agreements and covenants set forth in this Agreement shall survive the Closing hereunder
notwithstanding any due diligence investigation conducted by or on behalf of Investor. Company agrees to indemnify and hold harmless Investor
and all its officers, directors, employees, attorneys, and agents for loss or damage arising as a result of or related to any breach or
alleged breach by Company of any of its representations, warranties and covenants set forth in this Agreement or any of its covenants
and obligations under this Agreement, including advancement of expenses as they are incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">9.12. <U>Further Assurances</U>.
Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute and deliver all
such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to carry out the intent
and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">9.13. <U>Investor&rsquo;s
Rights and Remedies Cumulative</U>. All rights, remedies, and powers conferred in this Agreement and the Transaction Documents are cumulative
and not exclusive of any other rights or remedies, and shall be in addition to every other right, power, and remedy that Investor may
have, whether specifically granted in this Agreement or any other Transaction Document, or existing at law, in equity, or by statute,
and any and all such rights and remedies may be exercised from time to time and as often and in such order as Investor may deem expedient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">9.14. <U>Attorneys&rsquo;
Fees and Cost of Collection</U>. In the event any suit, action or arbitration is filed by either party against the other to interpret
or enforce any of the Transaction Documents, the unsuccessful party to such action agrees to pay to the prevailing party all costs and
expenses, including attorneys&rsquo; fees incurred therein, including the same with respect to an appeal. The &ldquo;prevailing party&rdquo;
shall be the party in whose favor a judgment is entered, regardless of whether judgment is entered on all claims asserted by such party
and regardless of the amount of the judgment; or where, due to the assertion of counterclaims, judgments are entered in favor of and against
both parties, then the arbitrator shall determine the &ldquo;prevailing party&rdquo; by taking into account the relative dollar amounts
of the judgments or, if the judgments involve nonmonetary relief, the relative importance and value of such relief. Nothing herein shall
restrict or impair an arbitrator&rsquo;s or a court&rsquo;s power to award fees and expenses for frivolous or bad faith pleading. If (i)
the Note is placed in the hands of an attorney for collection or enforcement prior to commencing arbitration or legal proceedings, or
is collected or enforced through any arbitration or legal proceeding, or Investor otherwise takes action to collect amounts due under
the Note or to enforce the provisions of the Note, or (ii) there occurs any bankruptcy, reorganization, receivership of Company or other
proceedings affecting Company&rsquo;s creditors&rsquo; rights and involving a claim under the Note; then Company shall pay the costs incurred
by Investor for such collection, enforcement or action or in connection with such bankruptcy, reorganization, receivership or other proceeding,
including, without limitation, attorneys&rsquo; fees, expenses, deposition costs, and disbursements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">9.15. <U>Waiver</U>.
No waiver of any provision of this Agreement shall be effective unless it is in the form of a writing signed by the party granting the
waiver. No waiver of any provision or consent to any prohibited action shall constitute a waiver of any other provision or consent to
any other prohibited action, whether or not similar. No waiver or consent shall constitute a continuing waiver or consent or commit a
party to provide a waiver or consent in the future except to the extent specifically set forth in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">9.16. <U>Waiver of
Jury Trial</U>. EACH PARTY TO THIS AGREEMENT IRREVOCABLY WAIVES ANY AND ALL RIGHTS SUCH PARTY MAY HAVE TO DEMAND THAT ANY ACTION,
PROCEEDING OR COUNTERCLAIM ARISING OUT OF OR IN ANY WAY RELATED TO THIS AGREEMENT, ANY OTHER TRANSACTION DOCUMENT, OR THE
RELATIONSHIPS OF THE PARTIES HERETO BE TRIED BY JURY. THIS WAIVER EXTENDS TO ANY AND ALL RIGHTS TO DEMAND A TRIAL BY JURY ARISING
UNDER COMMON LAW OR ANY APPLICABLE STATUTE, LAW, RULE OR REGULATION. FURTHER, EACH PARTY HERETO ACKNOWLEDGES THAT SUCH PARTY IS
KNOWINGLY AND VOLUNTARILY WAIVING SUCH PARTY&rsquo;S RIGHT TO DEMAND TRIAL BY JURY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">9.17. <U>Time is of
the Essence</U>. Time is expressly made of the essence with respect to each and every provision of this Agreement and the other Transaction
Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">9.18. <U>Voluntary
Agreement</U>. Company has carefully read this Agreement and each of the other Transaction Documents and has asked any questions needed
for Company to understand the terms, consequences and binding effect of this Agreement and each of the other Transaction Documents and
fully understand them. Company has had the opportunity to seek the advice of an attorney of Company&rsquo;s choosing, or has waived the
right to do so, and is executing this Agreement and each of the other Transaction Documents voluntarily and without any duress or undue
influence by Investor or anyone else.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 1in">9.19. <U>Document
Imaging</U>. Investor shall be entitled, in its sole discretion, to image or make copies of all or any selection of the agreements,
instruments, documents, and items and records governing, arising from or relating to any of Company&rsquo;s loans, including,
without limitation, this Agreement and the other Transaction Documents, and Investor may destroy or archive the paper originals. The
parties hereto (i) waive any right to insist or require that Investor produce paper originals, (ii) agree that such images
shall be accorded the same force and effect as the paper originals, (iii) agree that Investor is entitled to use such images in lieu
of destroyed or archived originals for any purpose, including as admissible evidence in any demand, presentment or other
proceedings, and (iv) further agree that any executed facsimile (faxed), scanned, emailed, or other imaged copy of this Agreement or
any other Transaction Document shall be deemed to be of the same force and effect as the original manually executed document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><I>[Remainder of page intentionally left blank; signature
page follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #161615">IN
WITNESS WHEREOF</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #2F2F2F">, </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #161615">the
undersigned Investor and Company have caused this Agreement to be duly executed as of the d</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #2F2F2F">a</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #161615">te
fir</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #2F2F2F">s</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #161615">t
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #2F2F2F">a</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #161615">bove
written</FONT>.</P>

<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0.15pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10.5pt Times New Roman, Times, Serif; margin: 0; color: #161615"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>SUBSCRIPTION
AMOUNT:</B></FONT></P>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Principal Amount of Note:</FONT></TD>
  <TD STYLE="width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD STYLE="width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #161615">$5,250,000</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #2F2F2F">.</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; color: #161615">00</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchase Price:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">$5<FONT STYLE="color: #2F2F2F">,</FONT><FONT STYLE="color: #161615">000,000</FONT><FONT STYLE="color: #626260">.</FONT><FONT STYLE="color: #161615">00</FONT></FONT></TD></TR>
</TABLE>

<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #161615">INVESTOR:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-variant: small-caps"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #161615"><B>STREETERVILLE CAPITAL,
    LLC</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #161615">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #161615">/s/
John M</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F">.</FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #161615">Fife</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #161615">John M</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F">.
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #161615">Fife, President</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #161615">COMPANY</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #4D4D4B">:</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-variant: small-caps"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #161615"><B>CHINA PHARMA HOLDINGS,
    INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #161615">By</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F">:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ <FONT STYLE="font-size: 10pt; color: #161615">Zh</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F">i</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #161615">lin
Li</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #161615">Zh</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #2F2F2F">i</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #161615">lin
    Li, CEO</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 7.5pt Times New Roman, Times, Serif; margin: 0.45pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: center; font: 7.5pt Times New Roman, Times, Serif; margin-top: 0.45pt; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt; color: #161615"><I>[Sig</I></FONT><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt; color: #2F2F2F">na</FONT></I><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt; color: #161615">tur</FONT></I><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt; color: #2F2F2F">e
</FONT></I><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt; color: #161615">Pag</FONT></I><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt; color: #2F2F2F">e
</FONT></I><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt; color: #161615">to S</FONT></I><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt; color: #2F2F2F">e</FONT></I><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt; color: #161615">cu</FONT></I><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt; color: #2F2F2F">r</FONT></I><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt; color: #161615">iti</FONT></I><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt; color: #2F2F2F">e</FONT></I><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt; color: #161615">s
Pu</FONT></I><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt; color: #2F2F2F">rc</FONT></I><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt; color: #161615">h</FONT></I><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt; color: #2F2F2F">ase
Agreeme</FONT></I><I><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10.5pt; color: #161615">nt]</FONT></I></P>

<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0.25pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0.25pt 0 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9.5pt Times New Roman, Times, Serif; margin: 0.25pt 0 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ATTACHED
EXHIBITS:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit A</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit B</FONT></TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Irrevocable Transfer Agent Instructions</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit C</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Secretary&rsquo;s Certificate</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit D</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share Issuance Resolution</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit E</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arbitration Provisions</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>EXHIBIT
E</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>ARBITRATION
PROVISIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0 0pt 0 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<U>Dispute Resolution</U>. For purposes of this <U>Exhibit E</U>, the term &ldquo;<B>Claims</B>&rdquo; means any disputes, claims, demands,
causes of action, requests for injunctive relief, requests for specific performance, liabilities, damages, losses, or controversies whatsoever
arising from, related to, or connected with the transactions contemplated in the Transaction Documents and any communications between
the parties related thereto, including without limitation any claims of mutual mistake, mistake, fraud, misrepresentation, failure of
formation, failure of consideration, promissory estoppel, unconscionability, failure of condition precedent, rescission, and any statutory
claims, tort claims, contract claims, or claims to void, invalidate or terminate the Agreement (or these Arbitration Provisions (defined
below)) or any of the other Transaction Documents. For the avoidance of doubt, Investor&rsquo;s pursuit of an injunction or other Claim
pursuant to these Arbitration Provisions or with a court will not later prevent Investor under the doctrines of claim preclusion, issue
preclusion, res judicata or other similar legal doctrines from pursuing other Claims in a separate arbitration in the future. The parties
to this Agreement (the &ldquo;<B>parties</B>&rdquo;) hereby agree that the Claims may be arbitrated in one or more Arbitrations pursuant
to these Arbitration Provisions (one for an injunction or injunctions and a separate one for all other Claims). The term &ldquo;Claims&rdquo;
specifically excludes a dispute over Calculations. The parties to the Agreement hereby agree that the arbitration provisions set forth
in this <U>Exhibit E</U> (&ldquo;<B>Arbitration Provisions</B>&rdquo;) are binding on each of them. As a result, any attempt to rescind
the Agreement (or these Arbitration Provisions) or declare the Agreement (or these Arbitration Provisions) or any other Transaction Document
invalid or unenforceable for any reason is subject to these Arbitration Provisions. These Arbitration Provisions shall also survive any
termination or expiration of the Agreement. Any capitalized term not defined in these Arbitration Provisions shall have the meaning set
forth in the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0 0pt 0 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9.5pt">2. <U>Arbitration</U>.
Except as otherwise provided herein, all Claims must be submitted to arbitration (&ldquo;<B>Arbitration</B>&rdquo;) to be conducted
exclusively in Salt Lake County, Utah and pursuant to the terms set forth in these Arbitration Provisions; <I>provided, however</I>,
that a virtual attendance option will be provided for all hearings. Subject to the arbitration appeal right provided for in
Paragraph 5 below (the &ldquo;<B>Appeal Right</B>&rdquo;), the parties agree that the award of the arbitrator rendered pursuant to
Paragraph 4 below (the &ldquo;<B>Arbitration Award</B>&rdquo;) shall be (a) final and binding upon the parties, (b) the sole and
exclusive remedy between them regarding any Claims, counterclaims, issues, or accountings presented or pleaded to the arbitrator,
and (c) promptly payable in United States dollars free of any tax, deduction or offset (with respect to monetary awards). Subject to
the Appeal Right, any costs or fees, including without limitation attorneys&rsquo; fees, incurred in connection with or incident to
enforcing the Arbitration Award shall, to the maximum extent permitted by law, </FONT>be charged against the party resisting such
enforcement. The Arbitration Award shall include default interest (as defined or otherwise provided for in the Note,
&ldquo;<B>Default Interest</B>&rdquo;) (with respect to monetary awards) at the rate specified in the Note for Default Interest both
before and after the Arbitration Award. Judgment upon the Arbitration Award will be entered and enforced by any state or federal
court sitting in Salt Lake County, Utah.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0 0pt 0 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif">3. <U>The
Arbitration Act</U>. The parties agree that these Arbitration Provisions will be governed by the Federal Arbitration Act, 9 U.S.C.
1-16 <I>et seq.</I> (as amended or superseded from time to time, the &ldquo;<B>Arbitration Act</B>&rdquo;). The parties hereby
incorporate herein the provisions and procedures set forth in the Arbitration Act. Notwithstanding the foregoing, pursuant to, and
to the maximum extent permitted by the Arbitration Act, in the event of conflict or variation between the terms of these Arbitration
Provisions and the provisions of the Arbitration Act, the terms of these Arbitration Provisions shall control and the parties hereby
waive or otherwise agree to vary the effect of all requirements of the Arbitration Act that may conflict with or vary from these
Arbitration Provisions.</FONT></P>

<P STYLE="font: 10pt Cambria, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.<U>
Arbitration Proceedings</U>. Arbitration between the parties will be subject to the following:</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 9.5pt Cambria, Times, Serif; margin: 0 0pt 0 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.1 <I>Initiation
of Arbitration</I>. The parties agree that a party may initiate Arbitration by giving written notice to the other party
(&ldquo;<B>Arbitration Notice</B>&rdquo;) in the same manner that notice is permitted under Section 9.9 of the
Agreement; <I>provided, however</I>, that the Arbitration Notice may not be given by email or fax. Arbitration </FONT>will be deemed
initiated as of the date that the Arbitration Notice is deemed delivered to such other party under Section 9.9 of
the Agreement (the &ldquo;<B>Service Date</B>&rdquo;). After the Service Date, information may be delivered, and notices may be
given, by email or fax pursuant to Section 9.9 of the Agreement or any other method permitted <FONT STYLE="font-family: Times New Roman, Times, Serif">thereunder.
The Arbitration Notice must describe the nature of the controversy, the remedies sought, and the election to commence Arbitration
proceedings. All Claims in the Arbitration Notice must be pleaded consistent with the Federal Rules of Civil Procedure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0 0 0 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.2 <FONT STYLE="font-size: 9.5pt"><I>Selection
and Payment of Arbitrator</I>.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0 0pt 0 0; text-align: justify; text-indent: 45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Within ten (10) calendar days after the Service Date, Investor shall select and submit to Company the names of three (3) arbitrators
that are designated as &ldquo;neutrals&rdquo; or qualified arbitrators by Utah ADR Services (http://www.utahadrservices.com) (such
three (3) designated persons hereunder are referred to herein as the &ldquo;<B>Proposed Arbitrators</B>&rdquo;). For the avoidance
of doubt, each Proposed Arbitrator must be qualified as a &ldquo;neutral&rdquo; with Utah ADR Services. Within five (5) calendar
days after Investor has submitted to Company the names of the Proposed Arbitrators, Company must select, by written notice to
Investor, one (1) of the Proposed Arbitrators to act as the arbitrator for the parties under these Arbitration Provisions. If
Company fails to select one of the Proposed Arbitrators in writing within such 5-day period, then Investor may select the arbitrator
from the Proposed Arbitrators by providing written notice of such selection to Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0 0pt 0 0; text-align: justify; text-indent: 45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9.5pt">(b)</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9.5pt">If
Investor fails to submit to Company the Proposed Arbitrators within ten (10) calendar days after the Service Date pursuant to
subparagraph (a) above, then Company may at any time prior to Investor so designating the Proposed Arbitrators, identify the names
of three (3) arbitrators that are designated as &ldquo;neutrals&rdquo; or qualified arbitrators by Utah ADR Service by written
notice to Investor. Investor may then, within five (5) calendar days after Company has submitted notice of its Proposed Arbitrators
to Investor, select, by written notice to Company, one (1) of the Proposed Arbitrators to act as the arbitrator for the parties
under these Arbitration Provisions. If Investor fails to select in writing and within such 5-day period one (1) of the three (3)
Proposed Arbitrators selected by Company, then Company may select the arbitrator from its three </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">(3)
previously selected Proposed Arbitrators by providing written notice of such selection to Investor.</FONT></P>



<P STYLE="font: 10pt Cambria, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0 0pt 0 0; text-align: justify; text-indent: 45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c)<FONT STYLE="font-size: 7pt">&nbsp;
</FONT>If a Proposed Arbitrator chosen to serve as arbitrator declines or is otherwise unable to serve as arbitrator, then the party
that selected such Proposed Arbitrator may select one (1) of the other three (3) Proposed Arbitrators within three (3) calendar days
of the date the chosen Proposed Arbitrator declines or notifies the parties he or she is unable to serve as arbitrator. If all three
(3) Proposed Arbitrators decline or are otherwise unable to serve as arbitrator, then the arbitrator selection process shall begin again
in accordance with this Paragraph 4.2.</FONT></P>

<P STYLE="font: 10pt Cambria, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0 0pt 0 0; text-align: justify; text-indent: 45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
The date that the Proposed Arbitrator selected pursuant to this Paragraph 4.2 agrees in writing (including via email) delivered to
both parties to serve as the arbitrator hereunder is referred to herein as the &ldquo;<B>Arbitration Commencement Date</B>&rdquo;.
If an arbitrator resigns or is unable to act during the Arbitration, a </FONT>replacement arbitrator shall be chosen in accordance
with this Paragraph 4.2 to continue the Arbitration. If Utah ADR Services ceases to exist or to provide a list of neutrals and there
is no successor thereto, then the arbitrator shall be selected under the then prevailing rules of the American Arbitration
Association.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0 0pt 0 0; text-align: justify; text-indent: 45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e)<FONT STYLE="font-size: 7pt"> </FONT>Subject
to Paragraph 4.10 below, the cost of the arbitrator must be paid equally by both parties. Subject to Paragraph 4.10 below, if one
party refuses or fails to pay its portion of the arbitrator fee, then the other party can advance such unpaid amount (subject to the
accrual of Default Interest thereupon), with such amount being added to or subtracted from, as applicable, the Arbitration
Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 9.5pt Cambria, Times, Serif; margin: 0 0pt 0 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.3
<I>Applicability of Certain Federal Rules</I>. The parties agree that the Arbitration shall be conducted generally in accordance with
the Federal Rules of Civil Procedure and the Federal Rules of Evidence. More specifically, the Federal Rules of Civil Procedure shall
apply, without limitation, to the filing of any pleadings, motions or memoranda, the conducting of discovery, and the taking of any depositions.
The Federal Rules of Evidence shall apply to any hearings, whether telephonic or in person, held by the arbitrator. Notwithstanding the
foregoing, it is the parties&rsquo; intent that the incorporation of such rules will in no event supersede these Arbitration Provisions.
In the event of any conflict between the Federal Rules of Civil Procedure or the Federal Rules of Evidence and these Arbitration Provisions,
these Arbitration Provisions shall control.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 9.5pt Cambria, Times, Serif; margin: 0 0pt 0 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.4
<I>Answer and Default</I>. An answer and any counterclaims to the Arbitration Notice shall be required to be delivered to the party initiating
the Arbitration within twenty (20) calendar days after the Arbitration Commencement Date. If an answer is not delivered by the required
deadline, the arbitrator must provide written notice to the defaulting party stating that the arbitrator will enter a default award against
such party if such party does not file an answer within five (5) calendar days of receipt of such notice. If an answer is not filed within
the five (5) day extension period, the arbitrator must render a default award, consistent with the relief requested in the Arbitration
Notice, against a party that fails to submit an answer within such time period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.5 </FONT><I>Related
Litigation</I>. The party that delivers the Arbitration Notice to the other party shall have the option to also commence concurrent legal
proceedings with any state or federal court sitting in Salt Lake County, Utah (&ldquo;<B>Litigation Proceedings</B>&rdquo;), subject to
the following: (a) the complaint in the Litigation Proceedings is to be substantially similar to the claims set forth in the Arbitration
Notice, provided that an additional cause of action to compel arbitration will also be included therein, (b) so long as the other party
files an answer to the complaint in the Litigation Proceedings and an answer to the Arbitration Notice, the Litigation Proceedings will
be stayed pending an Arbitration Award (or Appeal Panel Award (defined below), as applicable) hereunder, (c) if the other party fails
to file an answer in the Litigation Proceedings or an answer in the Arbitration proceedings, then the party initiating Arbitration shall
be entitled to a default judgment consistent with the relief requested, to be entered in the Litigation Proceedings, and (d) any legal
or procedural issue arising under the Arbitration Act that requires a decision of a court of competent jurisdiction may be determined
in the Litigation Proceedings. Any award of the arbitrator (or of the Appeal Panel (defined below)) may be entered in such Litigation
Proceedings pursuant to the Arbitration Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.6 </FONT><I>Discovery</I>.
Pursuant to Section 118(8) of the Arbitration Act, the parties agree that discovery shall be conducted as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a) </FONT>Written
discovery will only be allowed if the likely benefits of the proposed written discovery outweigh the burden or expense thereof, and the
written discovery sought is likely to reveal information that will satisfy a specific element of a claim or defense already pleaded in
the Arbitration. The party seeking written discovery shall always have the burden of showing that all of the standards and limitations
set forth in these Arbitration Provisions are satisfied. The scope of discovery in the Arbitration proceedings shall also be limited as
follows:</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 59pt"></TD><TD STYLE="width: 26.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(i)</FONT></TD><TD>To facts directly connected with the transactions contemplated by the Agreement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 59pt"></TD><TD STYLE="width: 26.95pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(ii)</FONT></TD><TD STYLE="text-align: justify">To facts and information that cannot be obtained from another
source or in another manner that is more convenient, less burdensome or less expensive than in the manner requested.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b) </FONT>No
party shall be allowed (i) more than fifteen (15) interrogatories (including discrete subparts), (ii) more than fifteen (15)
requests for admission (including discrete subparts), (iii) more than ten (10) document requests (including discrete subparts), or
(iv) more than three (3) depositions (excluding expert depositions) for a maximum of seven (7) hours per deposition. The costs
associated with depositions will be borne by the party taking the deposition. The party defending the deposition will submit a
notice to the party taking the deposition of the estimated attorneys&rsquo; fees that such party expects to incur in connection with
defending the deposition. If the party defending the deposition fails to submit an estimate of attorneys&rsquo; fees within five (5)
calendar days of its receipt of a deposition notice, then such party shall be deemed to have waived its right to the estimated
attorneys&rsquo; fees. The party taking the deposition must pay the party defending the deposition the estimated attorneys&rsquo;
fees prior to taking the deposition, unless such obligation is deemed to be waived as set forth in the immediately preceding
sentence. If the party taking the deposition believes that the estimated attorneys&rsquo; fees are unreasonable, such party may
submit the issue to the arbitrator for a decision. All depositions will be taken in New York City, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c) </FONT>All
discovery requests (including document production requests included in deposition notices) must be submitted in writing to the
arbitrator and the other party. The party submitting the written discovery requests must include with such discovery requests a
detailed explanation of how the proposed discovery requests satisfy the requirements of these Arbitration Provisions and the Federal
Rules of Civil Procedure. The receiving party will then be allowed, within five (5) calendar days of receiving the proposed
discovery requests, to submit to the arbitrator an estimate of the attorneys&rsquo; fees and costs associated with responding to
such written discovery requests and a written challenge to each applicable discovery request. After receipt of an estimate of
attorneys&rsquo; fees and costs and/or challenge(s) to one or more discovery requests, consistent with subparagraph (c) above, the
arbitrator will within three (3) calendar days make a finding as to the likely attorneys&rsquo; fees and costs associated with
responding to the discovery requests and issue an order that (i) requires the requesting party to prepay the attorneys&rsquo; fees
and costs associated with responding to the discovery requests, and (ii) requires the responding party to respond to the discovery
requests as limited by the arbitrator within twenty-five (25) calendar days of the arbitrator&rsquo;s finding with respect to such
discovery requests. If a party entitled to submit an estimate of attorneys&rsquo; fees and costs and/or a challenge to discovery
requests fails to do so within such 5-day period, the arbitrator will make a finding that (A) there are no attorneys&rsquo; fees or
costs associated with responding to such discovery requests, and (B) the responding party must respond to such discovery requests
(as may be limited by the arbitrator) within twenty-five (25) calendar days of the arbitrator&rsquo;s finding with respect to such
discovery requests. Any party submitting any written discovery requests, including without limitation interrogatories, requests for
production subpoenas to a party or a third party, or requests for admissions, must prepay the estimated attorneys&rsquo; fees and
costs, before the responding party has any obligation to produce or respond to the same, unless such obligation is deemed waived as
set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d) </FONT>In
order to allow a written discovery request, the arbitrator must find that the discovery request satisfies the standards set forth in these
Arbitration Provisions and the Federal Rules of Civil Procedure. The arbitrator must strictly enforce these standards. If a discovery
request does not satisfy any of the standards set forth in these Arbitration Provisions or the Federal Rules of Civil Procedure, the arbitrator
may modify such discovery request to satisfy the applicable standards, or strike such discovery request in whole or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 45pt"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(e) </FONT>Each
party may submit expert reports (and rebuttals thereto), provided that such reports must be submitted within sixty (60) days of the Arbitration
Commencement Date. Each party will be allowed a maximum of two (2) experts. Expert reports must contain the following: (i) a complete
statement of all opinions the expert will offer at trial and the basis and reasons for them; (ii) the expert&rsquo;s name and qualifications,
including a list of all the expert&rsquo;s publications within the preceding ten (10) years, and a list of any other cases in which the
expert has testified at trial or in a deposition or prepared a report within the preceding ten (10) years; and (iii) the compensation
to be paid for the expert&rsquo;s report and testimony. The parties are entitled to depose any other party&rsquo;s expert witness one
(1) time for no more than four (4) hours. An expert may not testify in a party&rsquo;s case-in-chief concerning any matter not fairly
disclosed in the expert report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.6 </FONT><I>Dispositive
Motions</I>. Each party shall have the right to submit dispositive motions pursuant Rule 12 or Rule 56 of the Federal Rules of Civil Procedure
(a &ldquo;<B>Dispositive Motion</B>&rdquo;). The party submitting the Dispositive Motion may, but is not required to, deliver to the arbitrator
and to the other party a memorandum in support (the &ldquo;<B>Memorandum in Support</B>&rdquo;) of the Dispositive Motion. Within seven
(7) calendar days of delivery of the Memorandum in Support, the other party shall deliver to the arbitrator and to the other party a memorandum
in opposition to the Memorandum in Support (the &ldquo;<B>Memorandum in Opposition</B>&rdquo;). Within seven (7) calendar days of delivery
of the Memorandum in Opposition, as applicable, the party that submitted the Memorandum in Support shall deliver to the arbitrator and
to the other party a reply memorandum to the Memorandum in Opposition (&ldquo;<B>Reply Memorandum</B>&rdquo;). If the applicable party
shall fail to deliver the Memorandum in Opposition as required above, or if the other party fails to deliver the Reply Memorandum as required
above, then the applicable party shall lose its right to so deliver the same, and the Dispositive Motion shall proceed regardless.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.7 </FONT><I>Confidentiality</I>.
All information disclosed by either party (or such party&rsquo;s agents) during the Arbitration process (including without limitation
information disclosed during the discovery process or any Appeal (defined below)) shall be considered confidential in nature. Each party
agrees not to disclose any confidential information received from the other party (or its agents) during the Arbitration process (including
without limitation during the discovery process or any Appeal) unless (a) prior to or after the time of disclosure such information becomes
public knowledge or part of the public domain, not as a result of any inaction or action of the receiving party or its agents, (b) such
information is required by a court order, subpoena or similar legal duress to be disclosed if such receiving party has notified the other
party thereof in writing and given it a reasonable opportunity to obtain a protective order from a court of competent jurisdiction prior
to disclosure, or (c) such information is disclosed to the receiving party&rsquo;s agents, representatives and legal counsel on a need
to know basis who each agree in writing not to disclose such information to any third party. The arbitrator is hereby authorized and directed
to issue a protective order to prevent the disclosure of privileged information and confidential information upon the written request
of either party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.8 </FONT><I>Authorization;
Timing; Scheduling Order</I>. Subject to all other portions of these Arbitration Provisions, the parties hereby authorize and direct
the arbitrator to take such actions and make such rulings as may be necessary to carry out the parties&rsquo; intent for the
Arbitration proceedings to be efficient and expeditious. For the avoidance of doubt, the arbitrator is empowered to decide any
procedural issues, jurisdictional issues, and issues regarding whether a particular dispute is subject to Arbitration. The parties
hereby agree that an Arbitration Award must be made within one hundred twenty (120) calendar days after the Arbitration Commencement
Date. The arbitrator is hereby authorized and directed to hold a scheduling conference within ten (10) calendar days after the
Arbitration Commencement Date in order to establish a scheduling order with various binding deadlines for discovery, expert
testimony, and the submission of documents by the parties to enable the arbitrator to render a decision prior to the end of such
120-day period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.9 </FONT><I>Relief</I>.
The arbitrator shall have the right to award or include in the Arbitration Award (or in a preliminary ruling) any relief which the arbitrator
deems proper under the circumstances, including, without limitation, specific performance and injunctive relief, provided that the arbitrator
may not award exemplary or punitive damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.10 </FONT><I>Fees
and Costs</I>. As part of the Arbitration Award, the arbitrator is hereby directed to require the losing party (the party being awarded
the least amount of money by the arbitrator, which, for the avoidance of doubt, shall be determined without regard to any statutory fines,
penalties, fees, or other charges awarded to any party) to (a) pay the full amount of any unpaid costs and fees of the Arbitration, and
(b) reimburse the prevailing party for all reasonable attorneys&rsquo; fees, arbitrator costs and fees, deposition costs, other discovery
costs, and other expenses, costs or fees paid or otherwise incurred by the prevailing party in connection with the Arbitration.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif">5.</FONT> <U>Arbitration Appeal</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.1 </FONT><I>Initiation
of Appeal.</I> Following the entry of the Arbitration Award, either party (the &ldquo;<B>Appellant</B>&rdquo;) shall have a period of
thirty (30) calendar days in which to notify the other party (the &ldquo;<B>Appellee</B>&rdquo;), in writing, that the Appellant elects
to appeal (the &ldquo;<B>Appeal</B>&rdquo;) the Arbitration Award (such notice, an &ldquo;<B>Appeal Notice</B>&rdquo;) to a panel of arbitrators
as provided in Paragraph 5.2 below. The date the Appellant delivers an Appeal Notice to the Appellee is referred to herein as the &ldquo;<B>Appeal
Date</B>&rdquo;. The Appeal Notice must be delivered to the Appellee in accordance with the provisions of Paragraph 4.1 above with respect
to delivery of an Arbitration Notice. In addition, together with delivery of the Appeal Notice to the Appellee, the Appellant must also
pay for (and provide proof of such payment to the Appellee together with delivery of the Appeal Notice) a bond in the amount of 110% of
the sum the Appellant owes to the Appellee as a result of the Arbitration Award the Appellant is appealing. In the event an Appellant
delivers an Appeal Notice to the Appellee (together with proof of payment of the applicable bond) in compliance with the provisions of
this Paragraph 5.1, the Appeal will occur as a matter of right and, except as specifically set forth herein, will not be further conditioned.
In the event a party does not deliver an Appeal Notice (along with proof of payment of the applicable bond) to the other party within
the deadline prescribed in this Paragraph 5.1, such party shall lose its right to appeal the Arbitration Award. If no party delivers an
Appeal Notice (along with proof of payment of the applicable bond) to the other party within the deadline described in this Paragraph
5.1, the Arbitration Award shall be final. The parties acknowledge and agree that any Appeal shall be deemed part of the parties&rsquo;
agreement to arbitrate for purposes of these Arbitration Provisions and the Arbitration Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.2 </FONT><I>Selection
and Payment of Appeal Panel.</I> In the event an Appellant delivers an Appeal Notice to the Appellee (together with proof of payment of
the applicable bond) in compliance with the provisions of Paragraph 5.1 above, the Appeal will be heard by a three (3) person arbitration
panel (the &ldquo;<B>Appeal Panel</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a) </FONT>Within
ten (10) calendar days after the Appeal Date, the Appellee shall select and submit to the Appellant the names of five (5) arbitrators
that are designated as &ldquo;neutrals&rdquo; or qualified arbitrators by Utah ADR Services (http://www.utahadrservices.com) (such five
(5) designated persons hereunder are referred to herein as the &ldquo;<B>Proposed Appeal Arbitrators</B>&rdquo;). For the avoidance of
doubt, each Proposed Appeal Arbitrator must be qualified as a &ldquo;neutral&rdquo; with Utah ADR Services, and shall not be the arbitrator
who rendered the Arbitration Award being appealed (the &ldquo;<B>Original Arbitrator</B>&rdquo;). Within five (5) calendar days after
the Appellee has submitted to the Appellant the names of the Proposed Appeal Arbitrators, the Appellant must select, by written notice
to the Appellee, three (3) of the Proposed Appeal Arbitrators to act as the members of the Appeal Panel. If the Appellant fails to select
three (3) of the Proposed Appeal Arbitrators in writing within such 5-day period, then the Appellee may select such three (3) arbitrators
from the Proposed Appeal Arbitrators by providing written notice of such selection to the Appellant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b) </FONT>If
the Appellee fails to submit to the Appellant the names of the Proposed Appeal Arbitrators within ten (10) calendar days after the
Appeal Date pursuant to subparagraph (a) above, then the Appellant may at any time prior to the Appellee so designating the Proposed
Appeal Arbitrators, identify the names of five (5) arbitrators that are designated as &ldquo;neutrals&rdquo; or qualified
arbitrators by Utah ADR Service (none of whom may be the Original Arbitrator) by written notice to the Appellee. The Appellee may
then, within five (5) calendar days after the Appellant has submitted notice of its selected arbitrators to the Appellee, select, by
written notice to the Appellant, three (3) of such selected arbitrators to serve on the Appeal Panel. If the Appellee fails to
select in writing within such 5-day period three (3) of the arbitrators selected by the Appellant to serve as the members of the
Appeal Panel, then the Appellant may select the three (3) members of the Appeal Panel from the Appellant&rsquo;s list of five (5)
arbitrators by providing written notice of such selection to the Appellee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(c) </FONT>If
a selected Proposed Appeal Arbitrator declines or is otherwise unable to serve, then the party that selected such Proposed Appeal Arbitrator
may select one (1) of the other five (5) designated Proposed Appeal Arbitrators within three (3) calendar days of the date a chosen Proposed
Appeal Arbitrator declines or notifies the parties he or she is unable to serve as an arbitrator. If at least three (3) of the five (5)
designated Proposed Appeal Arbitrators decline or are otherwise unable to serve, then the Proposed Appeal Arbitrator selection process
shall begin again in accordance with this Paragraph 5.2; <I>provided, however</I>, that any Proposed Appeal Arbitrators who have already
agreed to serve shall remain on the Appeal Panel.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(d) </FONT>The
date that all three (3) Proposed Appeal Arbitrators selected pursuant to this Paragraph <FONT STYLE="font-family: Times New Roman, Times, Serif">5.2 </FONT>agree
in writing (including via email) delivered to both the Appellant and the Appellee to serve as members of the Appeal Panel hereunder
is referred to herein as the &ldquo;<B>Appeal Commencement Date</B>&rdquo;. No later than five (5) calendar days after the Appeal
Commencement Date, the Appellee shall designate in writing (including via email) to the Appellant and the Appeal Panel the name of
one (1) of the three (3) members of the Appeal Panel to serve as the lead arbitrator in the Appeal proceedings. Each member of the
Appeal Panel shall be deemed an arbitrator for purposes of these Arbitration Provisions and the Arbitration Act, provided that, in
conducting the Appeal, the Appeal Panel may only act or make determinations upon the approval or vote of no less than the majority
vote of its members, as announced or communicated by the lead arbitrator on the Appeal Panel. If an arbitrator on the Appeal Panel
ceases or is unable to act during the Appeal proceedings, a replacement arbitrator shall be chosen in accordance with Paragraph 5.2
above to continue the Appeal as a member of the Appeal Panel. If Utah ADR Services ceases to exist or to provide a list of neutrals,
then the arbitrators for the Appeal Panel shall be selected under the then prevailing rules of the American Arbitration
Association.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 45pt">(d) Subject to Paragraph
5.7 below, the cost of the Appeal Panel must be paid entirely by the Appellant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.3 </FONT><I>Appeal
Procedure.</I> The Appeal will be deemed an appeal of the entire Arbitration Award. In conducting the Appeal, the Appeal Panel shall conduct
a de novo review of all Claims described or otherwise set forth in the Arbitration Notice. Subject to the foregoing and all other provisions
of this Paragraph 5, the Appeal Panel shall conduct the Appeal in a manner the Appeal Panel considers appropriate for a fair and expeditious
disposition of the Appeal, may hold one or more hearings and permit oral argument, and may review all previous evidence and discovery,
together with all briefs, pleadings and other documents filed with the Original Arbitrator (as well as any documents filed with the Appeal
Panel pursuant to Paragraph 5.4(a) below). Notwithstanding the foregoing, in connection with the Appeal, the Appeal Panel shall not permit
the parties to conduct any additional discovery or raise any new Claims to be arbitrated, shall not permit new witnesses or affidavits,
and shall not base any of its findings or determinations on the Original Arbitrator&rsquo;s findings or the Arbitration Award.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="margin-left: 0.25in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif">5.4</FONT> <I>Timing.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 47.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(a) </FONT>Within
seven (7) calendar days of the Appeal Commencement Date, the Appellant (i) shall deliver or cause to be delivered to the Appeal
Panel copies of the Appeal Notice, all discovery conducted in connection with the Arbitration, and all briefs, pleadings and other
documents filed with the Original Arbitrator (which material Appellee shall have the right to review and supplement if necessary),
and (ii) may, but is not required to, deliver to the Appeal Panel and to the Appellee a Memorandum in Support of the
Appellant&rsquo;s arguments concerning or position with respect to all Claims, counterclaims, issues, or accountings presented or
pleaded in the Arbitration. Within seven (7) calendar days of the Appellant&rsquo;s delivery of the Memorandum in Support, as
applicable, the Appellee shall deliver to the Appeal Panel and to the Appellant a Memorandum in Opposition to the Memorandum in
Support. Within seven (7) calendar days of the Appellee&rsquo;s delivery of the Memorandum in Opposition, as applicable, the
Appellant shall deliver to the Appeal Panel and to the Appellee a Reply Memorandum to the Memorandum in Opposition. If the Appellant
shall fail to substantially comply with the requirements of clause (i) of this subparagraph (a), the Appellant shall lose its right
to appeal the Arbitration Award, and the Arbitration Award shall be final. If the Appellee shall fail to deliver the Memorandum in
Opposition as required above, or if the Appellant shall fail to deliver the Reply Memorandum as required above, then the Appellee or
the Appellant, as the case may be, shall lose its right to so deliver the same, and the Appeal shall proceed regardless. <FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 47.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 47.2pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(b) </FONT>Subject
to subparagraph (a) above, the parties hereby agree that the Appeal must be heard by the Appeal Panel within thirty (30) calendar
days of the Appeal Commencement Date, and that the Appeal Panel must render its decision within thirty (30) calendar days after the
Appeal is heard (and in no event later than sixty (60) calendar days after the Appeal Commencement Date).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.5 </FONT><I>Appeal
Panel Award. </I>The Appeal Panel shall issue its decision (the &ldquo;<B>Appeal Panel Award</B>&rdquo;) through the lead arbitrator on
the Appeal Panel. Notwithstanding any other provision contained herein, the Appeal Panel Award shall (a) supersede in its entirety and
make of no further force or effect the Arbitration Award (provided that any protective orders issued by the Original Arbitrator shall
remain in full force and effect), (b) be final and binding upon the parties, with no further rights of appeal, (c) be the sole and exclusive
remedy between the parties regarding any Claims, counterclaims, issues, or accountings presented or pleaded in the Arbitration, and (d)
be promptly payable in United States dollars free of any tax, deduction or offset (with respect to monetary awards). Any costs or fees,
including without limitation attorneys&rsquo; fees, incurred in connection with or incident to enforcing the Appeal Panel Award shall,
to the maximum extent permitted by law, be charged against the party resisting such enforcement. The Appeal Panel Award shall include
Default Interest (with respect to monetary awards) at the rate specified in the Note for Default Interest both before and after the Arbitration
Award. Judgment upon the Appeal Panel Award will be entered and enforced by a state or federal court sitting in Salt Lake County, Utah.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.6 </FONT><I>Relief.</I>
The Appeal Panel shall have the right to award or include in the Appeal Panel Award any relief which the Appeal Panel deems proper under
the circumstances, including, without limitation, specific performance and injunctive relief, provided that the Appeal Panel may not award
exemplary or punitive damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.7 </FONT><I>Fees
and Costs.</I> As part of the Appeal Panel Award, the Appeal Panel is hereby directed to require the losing party (the party being
awarded the least amount of money by the arbitrator, which, for the avoidance of doubt, shall be determined without regard to any
statutory fines, penalties, fees, or other charges awarded to any party) to (a) pay the full amount of any unpaid costs and fees of
the Arbitration and the Appeal Panel, and (b) reimburse the prevailing party (the party being awarded the most amount of money by
the Appeal Panel, which, for the avoidance of doubt, shall be determined without regard to any statutory fines, penalties, fees, or
other charges awarded to any part) the reasonable attorneys&rsquo; fees, arbitrator and Appeal Panel costs and fees, deposition
costs, other discovery costs, and other expenses, costs or fees paid or otherwise incurred by the prevailing party in connection
with the Arbitration (including without limitation in connection with the Appeal).</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif">6.</FONT> <U>Miscellaneous</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.1 </FONT><I>Severability.</I>
If any part of these Arbitration Provisions is found to violate or be illegal under applicable law, then such provision shall be modified
to the minimum extent necessary to make such provision enforceable under applicable law, and the remainder of the Arbitration Provisions
shall remain unaffected and in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.2 </FONT><I>Interpretation</I>.
The headings of these Arbitration Provisions are for convenience of reference only and shall not form part of, or affect the interpretation
of, these Arbitration Provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.3 </FONT><I>Waiver</I>.
No waiver of any provision of these Arbitration Provisions shall be effective unless it is in the form of a writing signed by the party
granting the waiver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.4 </FONT><I>Time
is of the Essence</I>. Time is expressly made of the essence with respect to each and every provision of these Arbitration Provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[<I>Remainder of page intentionally
left blank</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>cphi-20211117.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qA5s7xRiXgen8uKa3EsWaePyaPtzplyCZlBtmd4bdnK/y8g5FvcNC9wY+d20UoE -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:CPHI="http://chinapharmaholdings.com/20211117" elementFormDefault="qualified" targetNamespace="http://chinapharmaholdings.com/20211117">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://chinapharmaholdings.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="cphi-20211117_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="cphi-20211117_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>cphi-20211117_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>cphi-20211117_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.10b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://chinapharmaholdings.com/role/Cover" xlink:href="cphi-20211117.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://chinapharmaholdings.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>ea151262-8k_chinapharma_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cphi-20211117.xsd" xlink:type="simple"/>
    <context id="From2021-11-17to2021-11-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001106644</identifier>
        </entity>
        <period>
            <startDate>2021-11-17</startDate>
            <endDate>2021-11-17</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-11-17to2021-11-17">0001106644</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-11-17to2021-11-17">false</dei:AmendmentFlag>
    <dei:EntityAddressCountry contextRef="From2021-11-17to2021-11-17" id="xdx2ixbrl0018">CN</dei:EntityAddressCountry>
    <dei:DocumentType contextRef="From2021-11-17to2021-11-17">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2021-11-17to2021-11-17">2021-11-17</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2021-11-17to2021-11-17">CHINA PHARMA HOLDINGS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-11-17to2021-11-17">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2021-11-17to2021-11-17">001-34471</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-11-17to2021-11-17">73-1564807</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-11-17to2021-11-17">Second Floor, No. 17</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-11-17to2021-11-17">Jinpan Road</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-11-17to2021-11-17">Hainan Province</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="From2021-11-17to2021-11-17">570216</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-11-17to2021-11-17">86</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-11-17to2021-11-17">898-6681-1730</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2021-11-17to2021-11-17">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2021-11-17to2021-11-17">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2021-11-17to2021-11-17">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2021-11-17to2021-11-17">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2021-11-17to2021-11-17">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-11-17to2021-11-17">CPHI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-11-17to2021-11-17">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-11-17to2021-11-17">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140263355979768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 17, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 17,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-34471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CHINA PHARMA HOLDINGS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001106644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">73-1564807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Second Floor, No. 17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Jinpan Road<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hainan Province<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">570216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">898-6681-1730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CPHI<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
MT8-W4PQ=\_)"!   PQ   !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6R=
MF%USVC@4AJ^[OT+#U>X,Q);Y3 >8(804M@EA@+:SN[,7PA:@B2U1603X]WMD
MP*:M.6;V)EBVS^M'1])[I+1W2K_%:\X-V4>AC#NEM3&;CXX3^VL>L?A.;;B$
M)TNE(V:@J5=.O-&<!4E0%#J>ZS:<B E9ZK:3>Q/=;:NM"87D$TWB;10Q?7C@
MH=IU2K1TOC$5J[6Q-YQN>\-6?,;-E\U$0\M)50(1<1D+)8GFRTZI1S\^>'4;
MD+SQ5?!=?'%-;%<62KW9QBCHE%Q+Q$/N&RO!X.>=]WD86B7@^'X2+:7?M(&7
MUV?UIZ3ST)D%BWE?A=]$8-:=4JM$ KYDV]!,U6[(3QU* 'T5QLE?LCN^6ZN5
MB+^-C8I.P4 0"7G\9?M3(BX"O-:5 .\4X"7<QP\EE(_,L&Y;JQW1]FU0LQ=)
M5Y-H@!/2CLK,:'@J(,YT^^J=Z[9C0,K></Q3V,,QS+L2-E;O=X0VR\1S/?IC
MN ,$*8:78GB)7A7#(/_T%K'1,%#_(I+55+*:2-:N2#XJ?PO3QY#Y8</S>HB'
MMRJ?$8A:"E%#57I $"043R%;Y5'@\4L6QASAJ*<<]=N2,>%:J( ,9$!@ON3F
M!5<ZC_QO'SX4C'TC96N@B@-IA#F0)Q%R,MY&B_SYB&NX+JU4:[4FQM-,>9JW
M\$SY2MC9"$D;LR@W4[A.?S@:]\ADV)N^],CP]?EQ-/XT*Y/1N'^'4+92RM8M
ME'T85,U",I(!WY//_)#'B2NYD#SJ-AJU&H)UGV+=WX(U9WLR"H!-+(7/$O^]
M/K2X8K-:H?5&K>4V$3SJ9G[GW@(XDK[2&Z43MC*9&5@,1&G25UM(*.15!;E#
M7J ^_HI!7I@RO06R%P2:QW'Y?$&>X3WR*O/)<,D9]Q4L^J=0*5TF8V47,<::
M.3?U_C_K?*=R67')/X7<,$FFB@488E8)*.[E/R/V;0L&>ZYV,A</EQO"9@?P
M)EJ]"^EC]DRS.D%QH_\%\3@/<^EPI?X8 \H*!L5]_F>@B8H-^,S?8G-];>"*
M]2;4BP8&EU4,BMM],H ]V(5>9\$%6BA'5BDH;O'/RH><3-9*8J6K0*1UWZHT
M&BU:H<VJBV%EI8'BCOY-"V.XA.1$T5:>##C.1<.%BK8?-"L+%'?QF0J%+XR0
M*_("5JL%"W-Y<)4B'B\K QYNU!/-*SZDA\,"/NX28:,&6]#7Y3)_$ OT"LDR
M[_=PH_Z%;!3'6R K!,1E"P$OMNJX.\^%@9V:6A+J_;[X@T!AV<)\R[6J B4[
M/V%G,#/*?\/0,J/W<&>>:Q;8*38[1 N5.\$*!/J3X0@CR?S<PUWXG!4RV/MK
M)E?\ZB:R0&C\UVS0>QE,,:K,U+V;3'T0<;VR>?H$"F9M?0+J;?X(XH)79Y5S
M<22UQ_L79K\8DY O0<B]:X*N/IZ8CPVC-LDI=:$,G'F3RS5G,./M"_!\J90Y
M-^S!-_V_1?<_4$L#!!0    ( -&#=U.?H!OPL0(  .(,   -    >&PO<W1Y
M;&5S+GAM;-U7;6O;,!#^*T(_8&YB:N*1&+9 8;"-0O-A7Y58=@1Z\62Y<_KK
MI[-L)VEU9=V'L<VAR=T]NKM'=R>9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8
M^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L
M*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:
ML!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI
M\0QKRTZ+Y2T].PP_/LG>V)+;.<V"3J9B+7D%=*RHC_#K3), Z)Q17B@%JXUF
M X?)8Q1\V .7\@%:^*VZBMU7)/3B4PEM(+#52?2$1C&$"0K$OXP68E^$O?VM
ML*01C\9][/QN]*!_[XSC]Y97HA_TOIKS8]$7>'36-/+T08I:*Q[V_LL)BS6;
M_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2
M]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=
MV_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>
M;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*
M(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D
M>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8
MJ;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8*<D3?,\C@ 69Y"F& *G$4<P
M!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0    ( -&#=U.7BKL<P    !,"
M   +    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8
M$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*N
MU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I
M2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3
MZ:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ T8-W4ZK$
M(A8S 0  (@(   \   !X;"]W;W)K8F]O:RYX;6R-4=%NPC ,_)4J'[ 6M"$-
M45Y VY"F#8V)]]"ZU"*)*\>%C:^?VZH:TE[VE-S9NMQ=%A?BTX'HE'QY%V)N
M:I%FGJ:QJ,';>$<-!)U4Q-Z*0CZFL6&P9:P!Q+MTFF6SU%L,9KD8M;:<W@(2
M* 0I*-D1>X1+_)UW,#ECQ ,ZE._<]'<')O$8T.,5RMQD)HDU75Z(\4I!K-L5
M3,[E9C(,]L""Q1]ZUYG\M(?8,V(/'U:-Y&:6J6"%'*7?Z/6M>CR#+@^H%7I"
M)\!K*_#,U#88CIV,IDAO8O0]C.=0XIS_4R-5%1:PIJ+U$&3HD<%U!D.LL8DF
M"=9#;E9T!N[RZ .;<L@F:NJF*9ZC#GA3#O9&3R54&*!\4YFHO/93;#GICEYG
M>O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0    ( -&#=U,D'INBK0   /@!
M   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U
M4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&
MRF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#='7=
M:7PX_;(X\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M
M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " #1@W=399!YDAD!
M  #/ P  $P   %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\295LE+BQ8
MH*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&PZ)WUV)0=
M47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5,[1R;ZEX
MZ7D;3?!-F<!B63R-PLQJ2AFC-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=
M<.I[.T!*1D.QD8E>I6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1
M=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#
MOI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4
M Q0    ( -&#=U,'04UB@0   +$    0              "  0    !D;V-0
M<F]P<R]A<' N>&UL4$L! A0#%     @ T8-W4UZ#.Y+M    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ T8-W
M4YE<G",0!@  G"<  !,              ( !RP$  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " #1@W=3#%WS\D($  ##$   &
M@($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ T8-W
M4Y^@&_"Q @  X@P   T              ( !A P  'AL+W-T>6QE<RYX;6Q0
M2P$"% ,4    " #1@W=3EXJ[',     3 @  "P              @ %@#P
M7W)E;',O+G)E;'-02P$"% ,4    " #1@W=3JL0B%C,!   B @  #P
M        @ %)$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ T8-W4R0>
MFZ*M    ^ $  !H              ( !J1$  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ T8-W4V60>9(9 0  SP,  !,
M     ( !CA(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @
&V!,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea151262-8k_chinapharma.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://chinapharmaholdings.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ea151262-8k_chinapharma.htm">ea151262-8k_chinapharma.htm</File>
    <File>cphi-20211117.xsd</File>
    <File>cphi-20211117_lab.xml</File>
    <File>cphi-20211117_pre.xml</File>
    <File>ea151262ex10-1_chinapharma.htm</File>
    <File>ea151262ex4-1_chinapharma.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ea151262-8k_chinapharma.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "ea151262-8k_chinapharma.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cphi-20211117_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cphi-20211117_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cphi-20211117.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "CPHI",
   "nsuri": "http://chinapharmaholdings.com/20211117",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea151262-8k_chinapharma.htm",
      "contextRef": "From2021-11-17to2021-11-17",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://chinapharmaholdings.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea151262-8k_chinapharma.htm",
      "contextRef": "From2021-11-17to2021-11-17",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r11",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://chinapharmaholdings.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r14": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r15": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001213900-21-061610-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-21-061610-xbrl.zip
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M;-\E=@5%OV$-!ZP, I)>>R8L,F <U2)0$8+R&+_8S--T2\2;X+&$>$((- ^
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MT#30I,E4'M8\N<X#D8KTF<VHGMP>7N(U1(Y7QA:#QL*XI@B"$= 6M"RN_U:
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M^Z?<F:'-VT*+'NI+0:. DJY"1>-<6[=V\@<OK3MV4-Z(B6F5,)P]4]F8LWC
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M?$ #$A?#8?F>2$116CUJX#UO,3VF'BF]PW07Q&_ZHRRYL6578FE@R^+>&.P
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MAA23KVEE8G]PAN0DJ^J("8V]UQ1*B"[HO115K<5F DGDO )'&(O#N03>FU9
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M$UR)#HF1IR5L#.I<Z-AEOL?LPBX-APB)"T_2*DLBY BH*WSU%23: 9+7HH@
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MD\8H!LQA%@H'\\5AE/&HS&WI%*84G C9=D"%(0?*&47G8(^ /$%?W##E\4$
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M>#-W^DLWV7$;^]XI[/'1(KSX*Z-IGJ?)A218=B]O?6T(4R>&'3*B()97LK[
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MS5T_''[P^K^/J;5<S#8JH;1P()&JM&#MV!T[&&11_N6EA7/!^W>FU4W5_R#
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M$P4;<3)*<\)TQ/:WO5ZC&\T2T!"^6 2(@E,BW19A,(K9H Z#)G(WWD $'Q8
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MV!%''[YQ1\FW6/Y/3);XP6NNQR7F? ,[ZR]YM99%!V8?[13^:/WVV>;.3:>
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M4)DDH,=8;[$2^ IFCIX=%1]%G*: "0L1ZCFTFOHA,JQ62[!'M^+DRA@/F+7
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M\V8M4@4PIK8,QU;K\2LY+TW:K9TPT^VHC ",/'%#= S8/C+IO2ZYRKHQ$86
MZA@76%74V&C/2;BXP\1ERTG@["W#6K2@.Q#^FJIMP<DF\/WJ8FZ%30W\O]./
M28/2Z/0W^QP[KV/\<-5Q7>.("]Q J8J=FABL$?#739)AW442J4#MW?BY9]1F
M3#5$Q(J-M1HYG4(MFW06V@Z[$V!=M9*Z%4DE4K#8RG.)'5RR56Z</E$9WF!3
M4@<1>N$U:<?L8M)HV^V6I=VU5XE-"AP3T"3GBS3@3#K @L(%U8XV2C(OT2.L
M#$/);L3FP7&T\+ P,L6T:).Z,&K#/E+ 7&TPERWS$[JJA+XEV@ZU+&C'&T&.
M8M7<31J([\:;(0%R"X#F 0O#F\6 MWZT&/#64PSX+[MK-Y2E='29PHF;QG/O
M0!_>;V\Q.7X= R=KX6!4&[18ZAS7 ]](I_-8I6//OHC %<>* K&&(G@RB1-T
M@!0]EK+8)VG,%3J8+1/4K0Y6$_'MFZ069C>T3NS2\DP412[!6C$"=J*; DG*
M,7N:*D8.R7;"07"B*37E6]6Q'//-#LS=#@EB6N,4JNFPH0;20KBGNBP#K,YN
MU4H>JVXINH'MQ816@U<;FQC):2\"D#1UG14M:R**JWZPC&]CI>C/001*FR_U
MP"OG 2=(SU;AQR#_%)6HV]MP# )!1-5Q*7HXK>XOC0>F!D18[=JD6Z&V+H<*
MIJ]9 JA&E1#C'/WU- N3_%C3?YJ(X;2O <JPC<,VF58.?<8_#J27FE0<8)\2
MH_Q66H_TO>VFC%>#[F[C@LM[S&OT6V1SJOPKX24XNE&"<5G!Z* 5BW;DE(M8
MP);*V'PQD%1WEB3:@U8*2K)T+Y12"?CY:LCN% M3GY1Y:D:D(5E]-&AM6%B.
M[::K."TN=M3J'KL^6-&T1) -B6JB\]]"WVF\3^[FEJI>2)OZ0L* 829X+11#
M;$088,BPS/Q8!1PQEP0$L64D@(%34B$"HT$H( S.JVSJXTYA)\9>5TRD7J2S
M?< \LH*A#UCYO(UVL*4VXU?.80%^/P@N03^-TD6D>GG6X&()!96\]A8L<=B@
MPIN&W*#R%:HZ!K[-=?1-QN(;I]LAV&-"I:)N#"#=-*QAZ "O-P/9GM,R:-?X
M\J!1\#0FP:7NXD&5%.36 L+^,\L_&?!WUBL4XIJJ&QM/,VEQ( #R,.M)$G,J
M G[D -#F&#I<T:A:+>]T6Y#^N<CC(F2W0(^YGC08:;UL![_L(D*U*AS('L+M
MZM?P=I9R5GI!+>&]W@:,3HN^YE5^ I9H7B"[Z&,8QL5\42IT-VQW-\]RC<\2
MI^QQ4&B1>&4]LE/U0IVJ83Z*2Y- OBN$D7I\%BS&Y9-+-4*-OWUVQ#!RJ$')
M!GX?87A6Y5/9;SO6.POJ97LW/JL3I)VF1 6 D52?5T/KW[0MW#>\F%ZJ7=O!
M#4@2RT(:3OA>T<6"><UBX7R[O-'/Y#>)*G'M*#<O-NOPFRK:$&=&_7A,,XM"
MO^XZ@H/%.(K?S5&JTO\7?6HPI8OL1M--NK$S):7F@:1C[Z T@$%;L%:UJT23
MU!GAW]1+'#7A^Z'>C031*TU2W1.XJ#0F4*%"5CLM1E4W8KF,^BKF?^;X/:NP
MSQ*8 P5YSI91HZTOI339!"^%$*-R"3)Z(6#SZ&60S 6GT,J9J#4U8W!H54Y%
M!;'+'T)2#39)M7=75S=9'A=3K*\IIA",#0%(5$BMLO[8ZBK#=PUC<%3\R'Z]
M7ZDFMS)\K1(M2U/#T:C&LLGM2\"88UO3J5\_GB !B'$KJ^F+??NX]DSG.QS$
ML"<A*5.[P0P,8MD^98[;+;VLA(3F9&#3<Q+;$%])<H%5M,[.]]Q-0[5<\<JJ
MTLF@(<])O&\C-+M5S JG%L;8.1Y#92OQA,1./)MG<,+!/";_FX6HBO8"-D"V
M*QE)%K&LEU=6&ZUC<W-0RZ6)@M/1#0&U^6/&8&6,./UA*8DXV(Y\)K:X:A_&
MV=Y KS$V3@=]@%@6?HW8[3J;MH7V2%!.]5(8"0[LM^J1I=J]F; AMZTO3"9;
M+<8D283S""P<N@#)(8+P]E$0BOI=<GZTU:LC5NIC!;&9E0S?2PR/J?U<X5=7
M=MM>L?XP^HR(&US *NA2VKAN&/G.\SB]EC3.QR40UI5 .$6A+2? 1,TE8EI!
MXR@LRYUE>C7WGL+7P:7(;$[DU8#>6<AUTW1.IW$D3KJ,JI$)'-KN1&3UN%,@
M$]@MKRB5-]]4$(_HI3IDV@@EXK@K15_V5'O 4!Q]#VN3;Q]CVW_W7R>T4BF7
MQ^ 7'V7V+8)X1$@\;P2$^O3&XW(F$&+=#OV2<ZJ*_W[[?/_=@Z+(+8*E+WZT
M8.F+IV#IG0S(_V9QN7_H_;%_=KAW>NK]\6'O9._H?:6*C32,T T\XHVX0/L[
M^AR-%R7CV(H2XJ)1WZ/8.1MN'^QY.WL'!\?#W=W]PU___FSM&?W]]'BXH_ZN
MF("9'%O+!/,"^$#]Z4M<)I=Q6$[QIVL_/WN',SA1PQ-2W3A(U%$ QG+/!LJD
M9\0I;\]V]4K@C_*1MW.$TS[\^[/U9^^VCTY.CO[8.WE-OX!_G=SGVZRO[_E5
MCA2Y"/(X0,H3;OCJ&#8#3MS[H\.S&_QL^]W.A_W#H7?\87CR<>A].#I !CCU
MO?W#G3X&<M\^QY'>?6\$5$_-,>4J/3?R",6Q9L 7R'\-D[K1PYOP[/;5ZZ8'
MK[L)]!@;+V"0Y\5S[_]-0;M*O8/XO@C=])%^J0^G_<AY\W,2"D\"I\I6-KNB
MSVOG/P^/_CC8V_UU;]?WACL[>\=G>[O>\!#^_^O)WM[N:]27E^[#US)ZRP'Z
M%J\[V#O<5<+U\2WO+H7LZ1DPP]G>R>_[!\CYP^/]L^$!F/4'.U49^TCH^.TE
MZ#^R:>I][(/F.(F^7)@WW@3W((7M6?K><1YA*17"5%V_%_<JDAN#8<H.^6(L
M]>46RW^=*EN23!*/L(=U)T3*S)[%V+^7X:K^^WLW+U]^*Z/R)L;5DSWWQ1S;
M9)R35!^>G0UW/GS<@TM@P'+\KW#D;+_;W7N_?[A_MG]T>/JUT_AV]G*U59SE
M\"='G@%D8H 37=W*<#7F^UD4H'^V>/UPUWT+[^MPT+=+MI.LH)RA[3AD?[65
M9$O.R=IOJ>HWJO\8R55(8D]1$OX,P3K'JK4-CN9\5=) TCM0T*ZYIRRC2]72
MAS-NLF" FV>4 .MS&1,"9+-#=CO),DQH/D?004I>;7K,&V%3"2Y9I#ZGU&>
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M:2TR,#(Q,3$Q-U]L86(N>&UL4$L! A0#%     @ T8-W4[P'/;]=!P  ZU<
M !4              ( !F0X  &-P:&DM,C R,3$Q,3=?<')E+GAM;%!+ 0(4
M Q0    ( -&#=U,-U&DPUQ<  $UW   ;              "  2D6  !E83$U
M,3(V,BTX:U]C:&EN87!H87)M82YH=&U02P$"% ,4    " #1@W=3/LO9'6UE
M  #>_@$ '@              @ $Y+@  96$Q-3$R-C)E>#$P+3%?8VAI;F%P
M:&%R;6$N:'1M4$L! A0#%     @ T8-W4X20S%5@00  &FD! !T
M     ( !XI,  &5A,34Q,C8R97@T+3%?8VAI;F%P:&%R;6$N:'1M4$L%!@
0   &  8 I0$  'W5      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
